Insys Therapeutics (INSY) 10-K 12 Mar 18 2017 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Mar. 02, 2018	Jun. 30, 2017
Document And Entity Information [Abstract]
Entity Registrant Name	Insys Therapeutics, Inc.
Entity Central Index Key	1,516,479
Trading Symbol	insy
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding (in shares)		73,764,390
Entity Public Float			$ 308

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current Assets:
Cash and cash equivalents	$ 31,999	$ 104,642
Short-term investments	85,189	78,238
Accounts receivable, net of allowances of $3,832 and $6,144 at December 31, 2017 and 2016, respectively	21,513	20,654
Inventories, net	17,408	20,414
Prepaid expenses and other current assets	19,833	5,695
Total current assets	175,942	229,643
Property and equipment, net	55,174	43,172
Long-term investments	46,733	53,796
Deferred income tax assets, net		23,243
Other assets	1,231	6,282
Total assets	279,080	356,136
Current Liabilities:
Accounts payable and accrued expenses	30,438	27,359
Accrued compensation	8,808	8,833
Accrued sales allowances	16,290	28,955
Deferred revenue	1,109
Accrued litigation awards and settlements	150,534	13,467
Total current liabilities	207,179	78,614
Uncertain income tax position	8,619	7,933
Total liabilities	215,798	86,547
Commitments and Contingencies (Note 7)
Stockholders' Equity:
Preferred stock (par value $0.01 per share; 10,000,000 shares authorized; 0 shares issued and outstanding as of December 31, 2017 and 2016, respectively)	0	0
Common stock (par value $0.01 per share; 100,000,000 shares authorized; 73,612,052 and 71,923,550 shares issued and outstanding as of December 31, 2017 and 2016, respectively)	736	719
Additional paid in capital	278,356	256,529
Unrealized loss on available-for-sale securities, net of tax	(438)	(302)
Notes receivable from stockholders	(21)	(21)
Retained earnings (accumulated deficit)	(215,351)	12,664
Total stockholders' equity	63,282	269,589
Total liabilities and stockholders' equity	$ 279,080	$ 356,136

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 3,832	$ 6,144
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	73,612,052	71,923,550
Common stock, shares outstanding (in shares)	73,612,052	71,923,550

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Statement [Abstract]
Net revenue	$ 140,693	$ 242,275	$ 330,323
Cost of revenue	20,643	25,393	28,854
Gross profit	120,050	216,882	301,469
Operating expenses:
Sales and marketing	48,870	69,651	80,668
Research and development	62,954	73,913	56,781
General and administrative	67,573	62,092	62,948
Charges related to litigation award and settlements	159,684	3,900	10,616
Total operating expenses	339,081	209,556	211,013
Operating income (loss)	(219,031)	7,326	90,456
Other income:
Interest income	1,881	1,039	502
Other income (expense), net	(45)	59	36
Total other income	1,836	1,098	538
Income (loss) before income taxes	(217,195)	8,424	90,994
Income tax expense	10,820	834	32,941
Net income (loss)	(228,015)	7,590	58,053
Unrealized loss on available-for-sale securities, net of tax	(136)	(150)	(128)
Total comprehensive income (loss)	$ (228,151)	$ 7,440	$ 57,925
Net income (loss) per common share:
Basic	$ (3.16)	$ 0.11	$ 0.81
Diluted	$ (3.16)	$ 0.10	$ 0.77
Weighted average common shares outstanding
Basic	72,259,063	71,618,793	71,592,581
Diluted	72,259,063	74,145,918	75,707,651

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]	Receivables from Stockholder [Member]	Retained Earnings [Member]
Balance at Dec. 31, 2014	$ 163,190	$ 707	$ 215,507	$ (24)	$ (21)	$ (52,979)
Balance (in shares) at Dec. 31, 2014		70,702,688
Exercise of stock options	$ 9,524	$ 16	9,508
Exercise of stock options (in shares)	1,607,683	1,607,683
Issuance of common stock- employee stock purchase plan	$ 2,647	$ 2	2,645
Issuance of common stock- employee stock purchase plan (in shares)		151,906
Excess tax benefits on stock options and awards	13,596		13,596
Stock based compensation - stock options and awards	21,882		21,882
Stock based compensation - stock options and awards (in shares)		5,781
Unrealized loss on available-for-sale securities, net of tax	(128)			(128)
Repurchase of common stock	(16,459)	$ (6)	(16,453)
Repurchase of common stock (in shares)		(560,200)
Net income (loss)	58,053					58,053
Balance at Dec. 31, 2015	252,305	$ 719	246,685	(152)	(21)	5,074
Balance (in shares) at Dec. 31, 2015		71,907,858
Exercise of stock options	$ 3,803	$ 6	3,797
Exercise of stock options (in shares)	637,721	637,721
Issuance of common stock- employee stock purchase plan	$ 2,280	$ 2	2,278
Issuance of common stock- employee stock purchase plan (in shares)		221,046
Tax deficiency on stock options and awards	(1,729)		(1,729)
Stock based compensation - stock options and awards	21,589		21,589
Unrealized loss on available-for-sale securities, net of tax	(150)			(150)
Repurchase of common stock	$ (16,099)	$ (8)	(16,091)
Repurchase of common stock (in shares)	(843,075)	(843,075)
Net income (loss)	$ 7,590					7,590
Balance at Dec. 31, 2016	269,589	$ 719	256,529	(302)	(21)	12,664
Balance (in shares) at Dec. 31, 2016		71,923,550
Exercise of stock options	$ 4,545	$ 15	4,530
Exercise of stock options (in shares)	1,476,448	1,476,448
Issuance of common stock- employee stock purchase plan	$ 1,326	$ 2	1,324
Issuance of common stock- employee stock purchase plan (in shares)		202,597
Stock based compensation - stock options and awards	16,015		16,015
Unrealized loss on available-for-sale securities, net of tax	$ (136)			(136)
Repurchase of common stock (in shares)	0
Vesting of restricted stock units (in shares)		14,000
Shares withheld for future payment of employees' withholding tax liability	$ (42)		(42)
Shares withheld for future payment of employees' withholding tax liability (in shares)		(4,543)
Net income (loss)	(228,015)					(228,015)
Balance at Dec. 31, 2017	$ 63,282	$ 736	$ 278,356	$ (438)	$ (21)	$ (215,351)
Balance (in shares) at Dec. 31, 2017		73,612,052

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities:
Net income (loss)	$ (228,015)	$ 7,590	$ 58,053
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Inventory obsolescence reserve	6,186	7,397	(336)
Depreciation and amortization	7,337	6,249	5,291
Stock-based compensation	16,015	21,589	21,882
Deferred income tax benefit	23,243	(5,636)	(4,914)
Loss on disposal of assets			41
Excess tax benefits (tax deficiency) on stock options and awards		1,729	(13,596)
Amortization of investment discount	1,125	2,029	1,431
Changes in operating assets and liabilities:
Accounts receivable	(859)	26,618	(23,770)
Inventories	2,251	7,647	(3,280)
Prepaid expenses and other current and noncurrent assets	(14,518)	(1,721)	1,345
Accounts payable, accrued expenses and other current and noncurrent liabilities	(11,603)	(18,487)	50,708
Deferred revenue	1,109
Accrued litigation award and settlements	137,067	3,900	9,423
Net cash provided by (used in) operating activities	(60,662)	58,904	102,278
Cash flows from investing activities:
Purchase of investments	(132,068)	(115,375)	(138,470)
Proceeds from sales of investments	32,471	7,948	25,492
Proceeds from maturities of investments	98,448	96,009	36,643
Purchases of property and equipment	(16,661)	(10,614)	(13,842)
Net cash used in investing activities	(17,810)	(22,032)	(90,177)
Cash flows from financing activities:
Proceeds from issuance of common stock	1,326	2,280	2,647
Excess tax benefits (tax deficiency) on stock options and awards		(1,729)	13,596
Shares withheld for future payment of employees' withholding tax liability	(42)
Proceeds from exercise of stock options	4,545	3,803	9,524
Repurchase of common stock		(16,099)	(16,459)
Net cash provided by (used in) financing activities	5,829	(11,745)	9,308
Change in cash and cash equivalents	(72,643)	25,127	21,409
Cash and cash equivalents, beginning of period	104,642	79,515	58,106
Cash and cash equivalents, end of period	31,999	104,642	79,515
Supplemental cash flow disclosures:
Cash paid for income taxes	2,110	10,742	$ 15,351
Non-cash capital expenditures	$ 2,678	$ 425

Note 1 - Nature of Business

Note 1 - Nature of Business	12 Months Ended
	Dec. 31, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Nature of Business	1. Nature of Business Insys Therapeutics, Inc., which was incorporated in Delaware in June 1990, and our subsidiaries (collectively, “we,” “us,” and “our”) maintain headquarters in Chandler, Arizona. We are a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products. We have two commercially marketed products: SUBSYS®, a proprietary sublingual fentanyl spray for BTCP in opioid-tolerant adult patients; and SYNDROS®, a proprietary, orally administered liquid formulation of dronabinol for the treatment of CINV and anorexia associated with weight loss in patients with AIDS.

Note 2 - Significant Accounting

Note 2 - Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Significant Accounting Policies	2. Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of Insys Therapeutics, Inc. and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in the accompanying consolidated financial statements. Reclassification Certain amounts in prior periods have been reclassified to conform to the current period presentation. Fair Value of Financial Instruments The carrying values of certain of our financial instruments, including cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate their fair value due to the short-term nature of these financial instruments. FASB ASC No. 820, “Fair Value Measurement” defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. It also establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1: Observable inputs such as quoted prices in active markets; Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. Revenue Recognition We recognize revenue from the sale of SUBSYS® and SYNDROS®. Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred and title has passed, (iii) the price is fixed or determinable and (iv) collectability is reasonably assured. SUBSYS® was commercially launched in March 2012, and is available through a U.S. Food and Drug Administration (“FDA”) mandated Risk Evaluation and Mitigation program known as the Transmucosal Immediate Release Fentanyl program (“TIRF REMS”). We sell SUBSYS® in the United States to wholesale pharmaceutical distributors and directly to specialty retail pharmacies (collectively, our customers) subject to rights of return within a period beginning six months prior to, and ending 12 months following, product expiration. SUBSYS® currently has a shelf life of 36 or 48 months from the date of manufacture, depending on the manufacture date. We record revenue for SUBSYS® at the time the customer receives the shipment. SYNDROS® was commercially launched in July 2017. We sell SYNDROS® in the United States to wholesale pharmaceutical distributors and directly to retail pharmacies, collectively our customers, subject to rights of return within a period beginning six months prior to, and ending We recognize estimated product sales allowances as a reduction of product sales in the same period the related revenue is recognized. Product sales allowances are based on amounts owed or to be claimed on the related sales. These estimates take into consideration the terms of our agreements with customers and third-party payers and the levels of inventory within the distribution channels that may result in future discounts taken. In certain cases, such as patient assistance programs, we recognize the cost of patient discounts as a reduction of revenue based on estimated utilization. If actual future results vary, we may need to adjust these estimates, which could have an effect on product revenue in the period of adjustment. Our product sales allowances include: Product Returns. We allow customers to return product for credit within six months before and up to 12 months following its product expiration date. With respect to SUBSYS®, we have monitored actual return history since product launch, which provides us with a basis to reasonably estimate future product returns, taking into consideration the shelf life of product at the time of shipment, shipment and prescription trends, estimated distribution channel inventory levels, and consideration of the introduction of competitive products. Given the limited sales history of SYNDROS®, the Company currently cannot reliably estimate expected returns of the product at the time of shipment. Because of the shelf life of our products and our return policy of issuing credits on returned product that is within six months before and up to 12 months after its product expiration date, there may be a significant period of time between when the product is shipped and when we issue credits on returned product. Accordingly, we may have to adjust these estimates, which could have an effect on product sales and earnings in the period of adjustments. The allowance for product returns is included in accrued sales allowances. Wholesaler and Retailer Discounts. We offer discounts to certain wholesale distributors and specialty retailers based on contractually determined rates. We accrue the discount as a reduction of receivables due from the wholesalers and retailers upon shipment to the respective wholesale distributors and retail pharmacies. Prompt Pay Discounts. We offer cash discounts to our customers, generally 2.0% of the sales price, as an incentive for prompt payment. We account for cash discounts by reducing accounts receivable by the full amount of the discount. Stocking Allowances. We may offer discounts and extended payment terms, generally in the month of the initial commercial launch of a new product and on the first order made by certain wholesale distributors and retail pharmacies based on contractually determined rates. We accrue the discount as a reduction of receivables due from the wholesalers and retailers upon shipment to the respective wholesale distributors and retail pharmacies. Patient Discount Programs . We offer discount card programs to patients, in which patients receive discounts on their prescriptions that are reimbursed by us to the retailer. We estimate the total amount that will be redeemed based on a historical percentage of actual redemption applied to inventory in the distribution and retail channels. The allowance for patient discount programs is included in accrued sales allowances. Rebates. We participate in certain rebate programs, which provide discounted prescriptions to qualified insured patients. Under these rebate programs, we pay a rebate to the third-party administrator of the program, generally two to three months after the quarter in which prescriptions subject to the rebate are filled. We estimate and accrue these rebates based on current contract prices, historical and estimated future percentages of products sold to qualified patients and estimated levels of inventory in the distribution channel. The allowance for rebates is included in accrued sales allowances. Chargebacks. We provide discounts primarily to authorized users of the FSS of the General Services Administration under an FSS contract negotiated by the Department of Veterans Affairs and various organizations under Medicaid contracts and regulations. These entities purchase products from the wholesale distributors at a discounted price, and the wholesale distributors then charge back to us the difference between the current retail price and the price the entity paid for the product. We estimate and accrue chargebacks based on estimated wholesaler inventory levels, current contract prices and historical chargeback activity. Estimated chargebacks are recognized as a reduction of revenue in the same period the related revenue is recognized. The allowance for chargebacks is included as a reduction to accounts receivable. Dronabinol SG Capsule Our Dronabinol SG Capsule product was commercially launched in December 2011, and we sold Dronabinol SG Capsule exclusively to Mylan in the United States under a supply and distribution agreement. We discontinued sales of Dronabinol SG Capsule in 2015 and do not have any current plans to manufacture or market this product in the future. Cash and Cash Equivalents We consider all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The carrying value of those investments approximates their fair market value due to their short maturity and liquidity. Cash and cash equivalents include cash on hand and amounts on deposit with financial institutions, which at times may exceed current FDIC coverage limits of $250,000. Short-Term and Long-Term Investments Our policy for short-term and long-term investments is to establish a high-quality portfolio that preserves principal, meets liquidity needs, avoids inappropriate concentrations and delivers an appropriate yield in relationship to our investment guidelines and market conditions. Short-term and long-term investments consist of corporate, various government agency and municipal debt securities, as well as certificates of deposit that have maturity dates that are greater than 90 days. Certificates of deposit and commercial paper are carried at cost which approximates fair value. We classify our marketable securities as available-for-sale in accordance with FASB ASC Topic 320, “Investments — Debt and Equity Securities”. Available-for-sale securities are carried at fair value with unrealized gains and losses reported in stockholders’ equity, net of related tax effects. There were no reclassifications on available-for-sale securities during the year ended December 31, 2017. Reclassifications on available-for-sale securities were insignificant during the year ended December 31, 2016. A decline in the market value of any available-for-sale security below cost that is deemed to be other than temporary, results in impairment of the fair value of the investment. We did not have any realized gains or losses or decline in values judged to be other than temporary during the years ended December 31, 2017, 2016 and 2015. If we had realized gains and losses and declines in value judged to be other than temporary, we would have been required to include those changes in other expense in the consolidated statements of comprehensive income (loss). Premiums and discounts are amortized or accreted over the life of the related available-for-sale security. The cost of securities sold is calculated using the specific identification method. At December 31, 2017, our certificates of deposit and commercial paper as well as our marketable securities have been recorded at an estimated fair value of $4,499,000, $85,189,000 and $46,733,000 in cash and cash equivalents, short-term investments and long-term investments, respectively. Accounts Receivable, Net Trade accounts receivable are recorded at the invoice amount net of allowances for wholesaler discounts, prompt pay discounts, stocking allowances, chargebacks and doubtful accounts. See “Revenue Recognition” above for a description of our wholesaler discounts, prompt pay discounts, stocking allowances and chargebacks. In the ordinary course of business, and consistent with industry practices, we may from time to time offer extended payment terms to our customers as an incentive for new product launches or in other circumstances. These extended payment terms do not represent a significant risk to the collectability of accounts receivable as of the period-end and are evaluated in accordance with ASC 605, “Revenue Recognition” as applicable. We evaluate the collectability of our accounts receivable based on a variety of factors including the length of time the receivables are past due, the financial health of the customer and historical experience. We write off accounts receivable against the allowance when a balance is determined to be uncollectable. Inventories, Net Inventories consist of raw materials, work-in-process and finished product and are valued at the lower of cost (first-in, first-out cost method) or NRV. Non-current inventories are those that are not expected to be consumed or sold within 12 months of the balance sheet date. In evaluating whether inventory should be classified as current or noncurrent, management considers factors such as historical and anticipated future sales compared to quantities on hand and the remaining shelf life of products on hand. Inventory costs are capitalized prior to regulatory approval and product launch based on management’s judgment of probable future commercial use and net realizable value of the inventory. Such judgment incorporates our knowledge and best estimate of where the relevant product is in the regulatory process, our required investment in the product, market conditions, competing products and our economic expectations for the product post-approval relative to the risk of manufacturing the product prior to approval. In evaluating the recoverability of inventories produced in preparation for product launches, we consider the probability that revenue will be obtained from the future sale of the related inventory together with the status of the product within the regulatory approval process, as well as the market for the product in its current state. We could be required to permanently write down previously capitalized costs related to pre-approval or pre-launch inventory upon a change in such judgment, due to a denial or delay of approval by regulatory bodies, a delay in commercialization, or other potential factors including product expiration. Inventories are reviewed periodically for potential excess, dated or obsolete status. Management evaluates the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price we expect to obtain for products in their respective markets compared with historical cost, and the remaining shelf life of products on hand. During the year ended December 31, 2017, the Company refined its estimate for inventory obsolescence. The new estimate more closely aligns remaining product shelf life with anticipated future production and sales. The Company evaluated this change in accordance with ASC 250, “Accounting Changes and Error Corrections” and, accordingly, accounted for this change as a change in estimate. As a result of this change, the Company increased the inventory reserves by approximately $2.1 million during the year ended December 31, 2017. Property and Equipment, Net Property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives. Maintenance and repairs that do not extend the life of assets are charged to expense when incurred. When property and equipment is disposed of, the related costs and accumulated depreciation are removed from the accounts and any gain or loss is reported in the period the transaction takes place. Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted cash flows expected to be generated by the asset. If the carrying amount exceeds its estimated future undiscounted cash flows, an impairment charge is recognized by the amount by which the carrying amount exceeds the fair value of the asset. Income Taxes We account for our deferred income tax assets and liabilities based on differences between the financial reporting and tax bases of assets and liabilities, and net operating losses (“NOLs”) and other tax credit carry forwards. These items are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the period that includes the enactment date. We record a valuation allowance to reduce the deferred income tax assets to the amount that is more likely than not to be realized. In making such determinations, management considers all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operating results. We recognize a tax benefit from uncertain tax positions when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position. Our policy is to classify interest and penalties associated with income tax liabilities as income tax expense (benefit) in the consolidated statements of comprehensive income (loss). Research and Development Expenses Research and development (“R&D”) costs are expensed when incurred. These costs consist of: (i) external research and development expenses incurred under agreements with third-party contract research organizations and investigative sites, third-party manufacturing organizations and consultants; (ii) employee-related expenses, which include salaries, benefits and stock-based compensation for the personnel involved in our preclinical and clinical drug development activities; (iii) facilities expense, depreciation and other allocated expenses; and (iv) equipment and laboratory supplies. Advertising and Marketing Advertising and marketing costs are expensed as incurred. Advertising expense totaled $993,000, $1,572,000 and $1,166,000 for the years ended December 31, 2017, 2016 and 2015, respectively. Legal Fees Legal fees are expensed as incurred. Accordingly, we do not accrue for estimated future legal fees to be incurred in connection with litigation and other related legal matters. Legal expense is reported in general and administrative expenses, and totaled $20,328,000, $22,840,000 and $19,448,000 for the years ended December 31, 2017, 2016 and 2015, respectively. Stock-Based Compensation Expenses Stock-based compensation cost is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the service or vesting period, which is generally three to four years, on a straight-line basis. We account for forfeitures when they occur. We use the Black-Scholes option pricing model for estimating the grant date fair value of stock options using the following assumptions: • Volatility - Prior to our IPO, we did not have a reliable history of market prices for our common stock. Following our IPO, while we have an active trading market, we do not have sufficient historical data to accurately estimate volatility for the period equivalent to the expected term of the stock option grants. Accordingly, we estimate the expected stock price volatility for our common stock by taking the median historical stock price volatility for industry peers based on daily price observations over a period equivalent to the expected term of the stock option grants. We intend to incorporate the volatility of our own common stock share price in future periods as we begin to have sufficient historical data available. • Expected term - The expected term is based on a simplified method allowed by the SEC due to insufficient historical data, and • Risk-free rate - The risk-free interest rate for the expected term of the option is based on the average market rate on U.S. treasury securities in effect during the quarter in which the options were granted. • Dividends - The dividend yield assumption is based on our history and expectation of paying no dividends. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting period. On an on-going basis, we evaluate our estimates, including those related to revenue recognition (which is affected by prescriptions dispensed, wholesaler discounts, patient discount programs, rebates, and chargebacks), inventories, legal liabilities and settlements, stock-based compensation expense, and deferred tax valuation allowances. We base our estimates on historical experience and on various other assumptions that are believed by management to be reasonable under the circumstances. Actual results could materially differ from those estimates. Segment Information FASB ASC No. 280, “Segment Reporting” establishes standards for reporting information about reportable segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group (“CODM”), in deciding how to allocate resources and in assessing performance. The CODM evaluates revenues and gross profits based on product lines and routes to market. Based on our integration and management strategies, we operate in a single reportable segment. Recently Adopted Accounting Pronouncements Effective January 1, 2017, we adopted ASU No. 2016-09, “Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting”. Among other requirements, the new guidance requires all tax effects related to share-based payments at settlement (or expiration) to be recorded through the income statement. Previously, tax benefits in excess of compensation cost ("windfalls") were recorded in equity, and tax deficiencies ("shortfalls") were recorded in equity to the extent of previous windfalls, and then to the income statement. As required, this change was applied prospectively to all excess tax benefits and tax deficiencies resulting from settlements. Under the new guidance, the windfall tax benefit is to be recorded when it arises, subject to normal valuation allowance considerations. Excess tax benefits that were not previously recognized because the related tax deduction had not reduced current taxes payable were recorded through a cumulative effect adjustment as of the date of the adoption. As required, upon adoption, this change was applied on a modified retrospective basis, with a cumulative effect adjustment of a change in accounting principle of approximately $368,000 as a deferred tax asset with a corresponding valuation allowance of $368,000, which were offset in retained earnings. Additionally, our consolidated statement of cash flows now presents excess tax benefits as an operating activity, adjusted prospectively with no adjustments made to prior periods. Additionally, ASU No. 2016-09 addressed the presentation of employee taxes paid on the statement of cash flows. We are now required to present the cost of shares withheld from the employee to satisfy the employees’ income tax liability as a financing activity on the consolidated statement of cash flows rather than as an operating cash flow. This change was applied on a retrospective basis, as required, but did not impact the consolidated statement of cash flows for year ended December 31, 2017. ASU 2016-09 also permits entities to make an accounting policy election related to how forfeitures will impact the recognition of compensation cost for stock-based compensation to either estimate the total number of awards for which the requisite service period will not be rendered, as currently required, or to account for forfeitures as they occur. Upon adoption of ASU 2016-09, we elected to change our accounting policy to account for forfeitures as they occur. As required, this change was applied on a modified retrospective basis; however, as of December 31, 2016, we had estimated no forfeitures relating to the outstanding equity awards. As a result, no adjustment was required. Going forward, the adoption of ASU 2016-09 could cause volatility in the effective tax rate, as the excess tax benefits associated with the exercise of stock options could generate a significant discrete income tax benefit in a particular interim period, potentially creating volatility in net income and net income per share period-to-period and period-over-period. Effective January 1, 2017, we adopted ASU No. 2015-11, “Inventory (Topic 330): Simplifying the Measurement of Inventory”. Prior to January 1, 2017, we measured inventory at the lower of cost or market. This guidance requires us to measure inventory at the lower of cost and NRV, which eliminates the need to determine replacement cost and evaluate whether it is above the ceiling (NRV) or below the floor (NRV less a normal profit margin). The guidance defines NRV as the “estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation.” The adoption of this guidance did not have a material impact on our consolidated financial statements. Recent Accounting Pronouncements In May 2017, the FASB issued ASU No. 2017-09, “Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting”, to provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. Specifically, the ASU requires modification accounting to a share-based payment award unless all of the following are the same immediately before and after the change: the award’s fair value; the award’s vesting conditions; and the award’s classification as an equity instrument or a liability instrument. The amendments should be applied prospectively to an award modified on or after the adoption date, and are effective for fiscal years beginning after December 15, 2017. We will adopt the new guidance on January 1, 2018. The adoption of this guidance will not have a material impact on our consolidated financial statements. The actual impact is subject to change prior to the filing of our 2018 first quarter results. In March 2017, the FASB issued ASU No. 2017-08, “Receivables—Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities”, to amend the amortization period for certain purchased callable debt securities held at a premium. The ASU shortens the amortization period for the premium to the earliest call date. Under current U.S. GAAP, entities generally amortize the premium as an adjustment of yield over the contractual life of the instrument. The amendments should be applied on a modified retrospective basis and are effective for fiscal years beginning after December 15, 2018. Early adoption is permitted, including adoption in an interim period. We are currently evaluating the impact of this amendment on our consolidated financial statements. In October 2016, the FASB issued ASU No. 2016-16, “Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory”, to improve the accounting for the income tax consequences of intra-entity transfers of assets other than inventory. Current U.S. GAAP prohibits the recognition of current and deferred income taxes for an intra-entity asset transfer until the asset has been sold to an outside party, which is an exception to the principle of comprehensive recognition of current and deferred income taxes in U.S. GAAP. The amendments in this update eliminate the exception for an intra-entity transfer of an asset other than inventory. The amendments should be applied on a modified retrospective transition basis, and are effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. We will adopt the new guidance on January 1, 2018. The adoption of this guidance will not have a material impact on our consolidated financial statements. The actual impact is subject to change prior to the filing of our 2018 first quarter results. In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments”. The amendments affect entities required to present a statement of cash flows and provides specific guidance on a variety of cash flow issues to reduce current and potential future diversity in practice. The amendments are effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The amendments should be applied using a retrospective transition method to each period presented. We will adopt the new guidance on January 1, 2018. The adoption of this guidance will not have a material impact on our consolidated financial statements. The actual impact is subject to change prior to the filing of our 2018 first quarter results. In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments”. The amendments affect entities holding financial assets and net investment in leases that are not accounted for at fair value through net income, and are effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years, and early adoption is permitted. ASU 2016-13 amends the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in the timelier recognition of losses. We are currently evaluating the impact of these amendments on our consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, “Leases: (Topic 842)”, to provide guidance on recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements, specifically differentiating between different types of leases. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from all leases. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee have not significantly changed from previous U.S. GAAP guidance. There continues to be a differentiation between finance leases and operating leases. However, the principal difference from previous guidance is that the lease assets and lease liabilities arising from operating leases should be recognized in the balance sheet. The accounting applied by a lessor is largely unchanged from that applied under previous U.S. GAAP guidance. The amendments will be effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, and early adoption is permitted. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. The modified retrospective approach includes a number of optional practical expedients that entities may elect to apply. These practical expedients relate to the identification and classification of leases that commenced before the effective date, initial direct costs for leases that commenced before the effective date, and the ability to use hindsight in evaluating lessee options to extend or terminate a lease or to purchase the underlying asset. An entity that elects to apply the practical expedients will, in effect, continue to account for leases that commence before the effective date in accordance with previous U.S. GAAP guidance unless the lease is modified, except that lessees are required to recognize a right-of-use asset and a lease liability for all operating leases at each reporting date based on the present value of the remaining minimum rental payments that were tracked and disclosed under previous U.S. GAAP guidance. While the effect of the pronouncement has not yet been quantified, the Company is continuing to evaluate the impact of recording the right-of-use-assets and liabilities on its financial position. The Company anticipates it will be required to record assets and liabilities for leases currently classified as operating leases. Commitments and Contingencies, In January 2016, the FASB issued ASU No. 2016-01, “Financial Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities”, which amended the Financial Instruments topic of the ASC to address certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. The amendments will be effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, and early adoption is not permitted. These amendments should be applied by means of a cumulative-effect adjustment to the balance sheet as of the beginning of the fiscal year of adoption. The amendments re

Note 3 - Short-term and Long-te

Note 3 - Short-term and Long-term Investments	12 Months Ended
	Dec. 31, 2017
Schedule Of Investments [Abstract]
Short-Term and Long-Term Investments	3. Short-Term and Long-Term Investments Investments consisted of the following at December 31, 2017 (in thousands): December 31, 2017 Cost Unrealized Gains Unrealized Losses Other- Than- Temporary Impairment Losses Fair Value Cash and Cash Equivalents Short-term Investments Long-term Investments Cash and cash equivalents $ 12,183 $ — $ — $ — $ 12,183 $ 12,183 $ — $ — Money market securities 15,317 — — — 15,317 15,317 — — Marketable securities: Certificates of deposit 18,447 — — — 18,447 — 7,474 10,973 Commercial paper 10,560 — — — 10,560 1,499 9,061 — Corporate securities 59,613 — (206 ) — 59,407 1,500 39,622 18,285 Federal agency securities 37,793 — (203 ) — 37,590 1,500 20,015 16,075 Municipal securities 10,446 — (29 ) — 10,417 — 9,017 1,400 Total marketable securities 136,859 — (438 ) — 136,421 4,499 85,189 46,733 $ 164,359 $ — $ (438 ) $ — $ 163,921 $ 31,999 $ 85,189 $ 46,733 Investments consisted of the following at December 31, 2016 (in thousands): December 31, 2016 Cost Unrealized Gains Unrealized Losses Other- Than- Temporary Impairment Losses Fair Value Cash and Cash Equivalents Short-term Investments Long-term Investments Cash and cash equivalents $ 49,331 $ — $ — $ — $ 49,331 $ 49,331 $ — $ — Money market securities 54,015 — — — 54,015 54,015 — — Marketable securities: Certificates of deposit 26,114 — — — 26,114 — 13,855 12,259 Commercial paper 1,485 — — — 1,485 — 1,485 — Corporate securities 39,562 — (135 ) — 39,427 500 25,681 13,246 Federal agency securities 30,660 4 (92 ) — 30,572 — 10,854 19,718 Municipal securities 35,811 2 (81 ) — 35,732 796 26,363 8,573 Total marketable securities 133,632 6 (308 ) — 133,330 1,296 78,238 53,796 $ 236,978 $ 6 $ (308 ) $ — $ 236,676 $ 104,642 $ 78,238 $ 53,796 The amortized cost and estimated fair value of the marketable securities, by maturity, are shown below (in thousands): December 31, 2017 December 31, 2016 Amortized Cost Fair Value Amortized Cost Fair Value Marketable securities: Due in one year or less $ 90,071 $ 89,937 $ 80,092 $ 80,027 Due after one year through 5 years 46,788 46,484 53,540 53,303 Due after 5 years through 10 years — — — — Due after 10 years — — — — $ 136,859 $ 136,421 $ 133,632 $ 133,330 The following table shows the gross unrealized losses and the fair value of our investments, with unrealized losses that are not deemed to be other-than-temporarily impaired aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position (in thousands): December 31, 2017 December 31, 2016 Less Than 12 Months Greater Than 12 Months Less Than 12 Months Greater Than 12 Months Fair Value Unrealized Loss Fair Value Unrealized Loss Fair Value Unrealized Loss Fair Value Unrealized Loss Marketable securities: Corporate securities $ 245 $ (153 ) $ 7,839 $ (52 ) $ 38,027 $ (134 ) $ 401 $ (1 ) Federal agency securities 26,244 (89 ) 11,346 (114 ) 26,449 (91 ) 1,217 (1 ) Municipal securities 50,537 (18 ) 1,145 (12 ) 30,373 (81 ) 100 — $ 77,026 $ (260 ) $ 20,330 $ (178 ) $ 94,849 $ (306 ) $ 1,718 $ (2 ) As of December 31, 2017 and 2016, we have concluded that the unrealized losses on our marketable securities are temporary in nature. Marketable securities are reviewed quarterly for possible other-than-temporary impairment. This review includes an analysis of the facts and circumstances of each individual investment such as the severity of loss, the expectation for that security’s performance and the creditworthiness of the issuer.

Note 4 - Fair Value Measurement

Note 4 - Fair Value Measurement	12 Months Ended
	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurement	4. Fair Value Measurement At December 31, 2017 and 2016, we held short-term and long-term investments, as described in Note 3, that are required to be measured at fair value on a recurring basis. We had no assets or liabilities measured at fair value on a nonrecurring basis at December 31, 2017 and 2016. Substantially all available-for-sale investments held by us at December 31, 2017 and 2016, have been valued based on Level 2 inputs. Available-for-sale securities classified within Level 2 of the fair value hierarchy are valued utilizing reports from an independent third-party public quotation service based on closing prices on the last business day of the period presented. In addition, we use the public quotation service to perform price testing by comparing quoted prices listed in reports provided by the asset managers that hold our investments to quotes listed through the public quotation service. These asset managers utilize an independent pricing source to obtain quotes for most fixed income securities, and utilize internal procedures to validate the prices obtained. Our Level 3 asset represents our investment in a long-term corporate convertible promissory note and a warrant to purchase shares issued in connection with the convertible promissory note, which converted to convertible preferred stock as of December 31, 2016. This stock is not listed on any security exchange. The fair value of the preferred stock approximates its carrying value at December 31, 2017 Our investments measured at fair value on a recurring basis subject to the disclosure requirements of ASC 820 at December 31, 2017 were as follows (in thousands): Fair Value Measurement at Reporting Date Total Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Marketable securities: Certificates of deposit $ 18,447 $ — $ 18,447 $ — Commercial paper 10,560 — 10,560 — Corporate securities 59,407 — 58,889 518 Federal agency securities 37,590 — 37,590 — Municipal securities 10,417 — 10,417 — Total assets measured at fair value $ 136,421 $ — $ 135,903 $ 518 Our investments measured at fair value on a recurring basis subject to the disclosure requirements of ASC 820 at December 31, 2016 were as follows (in thousands): Fair Value Measurement at Reporting Date Total Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Marketable securities: Certificates of deposit $ 26,114 $ — $ 26,114 $ — Commercial paper 1,485 — 1,485 — Corporate securities 39,427 — 38,927 500 Federal agency securities 30,572 — 30,572 — Municipal securities 35,732 — 35,732 — Total assets measured at fair value $ 133,330 $ — $ 132,830 $ 500 The following table presents additional information about assets measured at fair value on a recurring basis and for which we utilize Level 3 inputs to determine fair value for the years ended December 31, 2017 and 2016 (in thousands): December 31, 2017 2016 Convertible stock Balance, beginning of period $ 500 $ — Change in fair value 18 — Purchases — 500 Balance, end of period $ 518 $ 500

Note 5 - Inventories, Net

Note 5 - Inventories, Net	12 Months Ended
	Dec. 31, 2017
Inventory Disclosure [Abstract]
Inventories, Net	5. Inventories, Net Inventories are stated at lower of cost or NRV. Cost, which includes amounts related to materials and costs incurred by our contract manufacturers, is determined on a first-in, first-out basis. Inventories are reviewed periodically for potential excess, dated or obsolete status. Management evaluates the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price we expect to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand. The components of inventories, net of allowances, are as follows (in thousands): December 31, 2017 December 31, 2016 Finished goods $ 4,709 $ 8,408 Work-in-process 5,752 6,183 Raw materials and supplies 6,947 5,823 Total inventories 17,408 20,414 Plus: non-current raw materials and finished goods 826 6,257 $ 18,234 $ 26,671 As of December 31, 2017 and 2016, raw materials inventories consisted of raw materials used in the manufacture of the dronabinol API for SYNDROS® in our U.S.-based, state-of-the-art dronabinol manufacturing facility, the fentanyl API for SUBSYS®, and component parts and packaging materials used in the manufacture of both SUBSYS® and SYNDROS®. Work-in-process consists of actual production costs, including facility overhead and tooling costs of in-process dronabinol, SUBSYS® and SYNDROS® products. Finished goods inventories consisted of finished SUBSYS® and SYNDROS® products and deferred SYNDROS® cost of revenue of $59,000 and $0 as of December 31, 2017 and 2016, respectively. Non-current raw materials and finished goods represent those inventories not expected to be consumed or sold within 12 months of the balance sheet date and are included in other assets in our consolidated balance sheets. As of December 31, 2017, all work-in-process inventory is expected to be used within 12 months of the balance sheet date and, therefore, is classified as current inventory. We maintain an allowance for excess and obsolete inventory, as well as inventory where its cost is in excess of its NRV. Inventories at December 31, 2017 and 2016 were reported net of these reserves of $13,664,000 and $7,478,000, respectively. During the year ended December 31, 2017, we increased these reserves by $6,186,000, inclusive of an allowance of $2,100,000 resulting from a change in estimate as described in Note 2. During the year ended December 31, 2016, we increased reserves by $7,397,000. During the year ended December 31, 2015, we decreased these reserves by $336,000.

Note 6 - Property and Equipment

Note 6 - Property and Equipment	12 Months Ended
	Dec. 31, 2017
Property Plant And Equipment [Abstract]
Property and Equipment	6. Property and Equipment Property and equipment are comprised of the following (in thousands): Estimated Useful Life As of December 31, (in years) 2017 2016 Computer equipment 3 — 7 $ 3,523 $ 3,462 Scientific equipment 3 — 10 14,962 12,930 Furniture 3 — 10 3,446 3,128 Manufacturing equipment 7 — 10 25,159 20,583 Leasehold improvements * 35,595 23,243 Less: accumulated depreciation and amortization (27,511 ) (20,174 ) Total fixed assets $ 55,174 $ 43,172 * The estimated useful life of the leasehold improvements is the lesser of the lease term or the estimated useful life. Total depreciation and amortization expense for the years ended December 31, 2017, 2016 and 2015 was $7,337,000, $6,249,000 and $5,291,000, respectively. As of December 31, 2017 and 2016, respectively, there was $9,663,000 and $6,857,000 of construction in progress included in total fixed assets that had not been placed into service and was not subject to depreciation.

Note 7 - Commitments and Contin

Note 7 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2017
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	7. Commitments and Contingencies Lease Commitments We lease facilities under non-cancelable operating lease agreements. Future minimum commitments for these operating leases in place as of December 31, 2017, with a remaining non-cancelable lease term in excess of one year, are as follows (in thousands): Years ending December 31, 2018 $ 3,310 2019 3,405 2020 3,495 2021 2,526 2022 1,283 Thereafter 13,146 Total $ 27,165 The terms of certain lease agreements provide for rental payments on a graduated basis. We recognize rent expense on the straight-line basis over the lease period and have accrued for rent expense incurred but not paid. Landlord incentives are recorded as deferred rent and amortized on a straight-line basis over the lease term. Deferred rent was approximately $3,237,000 as of December 31, 2017 and $3,003,000 as of December 31, 2016. Rent expense under operating leases for the years ended December 31, 2017, 2016 and 2015 was approximately $3,335,000, $2,757,000, and $2,445,000, respectively. Letters of Credit As of December 31, 2017, we had a $400,000 unused letter of credit related to the requirements of our facility lease agreement. Material Agreements Aptar In October 2015, we entered into an amended and restated supply, development & exclusive licensing agreement with Aptargroup, Inc. (“Aptar”) which, among other things, extended our exclusive supply rights to the current sublingual device, currently utilized by SUBSYS®, as well as any new device(s) jointly developed by the two companies for a period of seven years. In addition to extending the term, this amendment added certain minimum purchase commitments and requires certain tiered royalties as a percentage of net revenue to be paid by us ranging from less than one percent to the low single digits, commencing in March 2016 through the term of this agreement, from our sales of SUBSYS® and future products that use the Aptar spray device technology. In January 2016, we assigned our rights, title, duties and obligations of supply, development & exclusive licensing agreement with Aptar from our parent to our manufacturing subsidiary as part of a corporate restructuring. In April 2017, we, through our manufacturing subsidiary, entered into a further amendment to our Aptar supply, development and exclusive licensing agreement. This amendment effectively eliminates any prior minimum purchase obligations that had been set forth in the amendment dated October 30, 2015, and beginning in 2019, replaces them with a new annual flat fee of up to $500,000 if the quantity of devices purchased in a calendar year is less than one million devices. As a result, the cumulative effect related to this amendment reduces our aggregated purchase commitment with Aptar from $20,790,000 to $9,000,000 through December 21, 2022. As of December 31, 2017, our remaining estimated annual contractual obligation under our agreement with Aptar was $7,500,000. All purchase commitments required under our agreements with Aptar were met during the year ended December 31, 2017. Renaissance (formerly DPT) In April 2015, we entered into an amendment to our manufacturing and supply agreement with Renaissance, which extends our existing manufacturing and supply agreement to produce SUBSYS® until the end of 2020. In addition to extending the term, this amendment added certain minimum purchase commitments. In January 2016, we assigned our rights, title, duties and obligations of our manufacturing and supply agreement with Renaissance from our parent to our manufacturing subsidiary as part of a corporate restructuring. In July 2016, we, through our manufacturing subsidiary, entered into a further amendment to our Renaissance manufacturing and supply agreement dated May 24, 2011, as amended. This amendment effectively eliminates any prior minimum purchase (and batch) obligations that had been set forth in the amendment dated April 30, 2015 and replaces it with a new annual purchase commitment of $4,000,000 per calendar year commencing January 1, 2017 through December 31, 2020. As a result, the cumulative effect related to this amendment reduces our aggregated minimum purchase commitments with Renaissance from $49,740,000 to $16,000,000 through December 31, 2020. As of December 31, 2017, our remaining estimated annual contractual obligation under our agreement with Renaissance was $12,000,000. During the year ended December 31, 2017, we recorded a loss of $1,035,000 in cost of revenue in these consolidated statements of comprehensive income (loss) for a portion of this commitment which represented firm, non-cancellable and unconditional purchase commitments for quantities in excess of our current forecasts for future demand. The following table sets forth our aggregate minimum purchase commitments with Renaissance and Aptar under these agreements (in thousands): Years ending December 31, 2018 $ 5,500 2019 6,000 2020 6,000 2021 2,000 2022 — Thereafter — Total $ 19,500 Defined Contribution Retirement Plans (401(k) Plan) We sponsor a 401(k) plan covering all full-time employees. Participants may contribute up to the legal limit. The 401(k) plan provides for employee contributions, and beginning October 2014, our matching contribution is 50 percent of the first 6 percent of earnings contributed by each participant. During the years ended December 31, 2017, 2016, and 2015, matching contribution plan expenses totaled approximately $647,000, $730,000 and $670,000, respectively. Legal Matters Other than the matters that we have disclosed below, we from time to time become involved in various ordinary course legal and administrative proceedings, which include intellectual property, commercial, governmental and regulatory investigations, employee related issues and private litigation, which we do not currently believe are either individually or collectively material. We record accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. If the reasonable estimate of a probable loss is a range, and no amount within the range is a better estimate, the minimum amount in the range is accrued. If a loss is not probable or a probable loss cannot be reasonably estimated, no liability is recorded. We have established reserves for certain of our legal matters. Our loss estimates are generally developed in consultation with outside counsel and outside accounting experts and are based on analyses of potential outcomes. As legal and governmental proceedings, disputes and investigations are inherently unpredictable and in part, beyond our control, unless otherwise indicated, we cannot reasonably predict the outcome of these legal proceedings, nor can we estimate the amount of loss, or range of loss, if any, that may result from these proceedings. While our liability in connection with certain claims cannot be currently estimated, the resolution in any reporting period of one or more of these matters could have a significant impact on our consolidated financial condition, results of operations and cash flows for that future period, could ultimately have a material adverse effect on our consolidated financial position and could cause the market value of our common shares to decline. While we believe we have valid defenses in these matters, litigation and governmental and regulatory investigations are inherently uncertain, and we may in the future incur material judgments or enter into material settlements of claims. Government Proceedings Like other companies in the pharmaceutical industry, we are subject to extensive regulation by national, state and local government agencies in the United States. As a result, interaction with government agencies occurs in the normal course of our operations. The following is a brief description of pending governmental investigations that we believe are potentially or actually material at this time. It is possible that criminal charges and substantial payments, fines and/or civil penalties or damages or exclusion from federal health care programs or other administrative actions, as well as a corporate integrity agreement, deferred prosecution agreement, or similar government mandated compliance document that institutes significant restrictions or obligations, could result for us from any government investigation or proceeding. In addition, even certain investigations that are not discussed below and which we do not deem to be material at this time could be determined to be material and could have a material adverse effect on our financial condition, results of operations and cash flows. HHS Investigation . We received a subpoena, dated December 9, 2013, from the Office of Inspector General of the HHS in connection with an investigation of potential violations involving HHS programs. This subpoena was issued in connection with an investigation by the U.S. Attorney’s Office for the Central District of California and requested documents regarding our business, including the commercialization of SUBSYS®. We continue to cooperate with this investigation and have produced substantial documents in response to the subpoena and have provided other requested information. HIPAA Investigation . On September 8, 2014, we received a subpoena issued pursuant to HIPAA from the U.S. Attorney’s Office for the District of Massachusetts. The subpoena requested documents regarding SUBSYS®, including our sales and marketing practices related to this product. This investigation also relates to activities in our patient services hub. We continue to cooperate with this investigation and have produced substantial documents in response to the subpoena and have provided other requested information. DOJ Investigation Accrual . We collectively refer to the HHS and HIPAA investigations discussed above as the “DOJ Investigation”. In connection with our cooperation, we have been engaged in discussions with the DOJ about these matters, including a resolution of potential liability exposure. Management accrued, as of September 30, 2017, an aggregate of $150,000,000, which represents our current best estimate of the minimum liability exposure which we expect to be paid out over five years in connection with the DOJ Investigation. This current best estimate, on the terms reflected in the foregoing sentence, reflects a minimum exposure at which management has determined a willingness to settle these matters. The accrual was recorded in accrued litigation award and settlements on our consolidated balance sheets and as an operating expense on our consolidated statements of comprehensive income (loss). There can be no assurance that future discussions with the government to resolve these matters will be successful, that the approvals we need will be obtained or that any potential settlement will be agreed to on terms and conditions acceptable to us or the DOJ. We are unable to predict when these matters will be resolved or what further action, if any, the government will take in connection with them. In addition, there are ongoing discussions related to contingency based payments to the government associated with future events, that if triggered, would require payments of up to $75,000,000 in the aggregate. At this time, we are unable to predict if these future events are probable and as a result, no accrual has been recorded. Based on the ongoing uncertainties and potentially wide range of outcomes and contingencies associated with any potential resolution of the matter under investigation by the DOJ, the ultimate amount of potential liability may materially exceed the $150,000,000 accrual we have established. This accrual does not currently meet the more likely than not standard for tax deductibility; therefore, we have recognized no tax benefit for it in these consolidated financial statements. Due to the uncertainty around the ultimate outcome of this matter, it is possible that some or all of this accrual may meet the more likely than not standard in the future, at which time the benefit would be recognized. Health Care Professionals and Former Employees Related Investigations. Investigations of Health Care Professionals . A number of health care practitioners who formerly interacted with our company are under investigation or have been charged in criminal proceedings. In addition to the below investigations that are specifically directed at us, we have received governmental agency requests for information, including subpoenas, from at least the following governmental bodies: the USAO and/or HHS OIG of California (Los Angeles), Connecticut, Eastern District of Michigan, Florida (Jacksonville), Kansas, Middle District of Pennsylvania, New Hampshire, New Jersey, Northern District of California, Northern District of Texas, Rhode Island, Southern District of Alabama, Southern District of New York, Southern District of Ohio, Western District of New York, and the States of Maryland and Delaware, regarding specific health care professionals that we have interacted with in those states. In addition, at least the following health care practitioners formerly interacting with our company have been charged as follows: On or about June 23, 2015, a nurse practitioner located in Connecticut, who served on our speaker bureau in connection with our speaker programs designed to educate and promote product awareness and safety for external health care providers, pled guilty to violating the federal Anti-Kickback Statute in connection with payments of approximately $83,000 from us. On February 23, 2017, two Alabama health care professionals, who served on our speaker bureau were convicted on 19 of 20 counts brought against them, which included charges related to distribution of a controlled substance, drug conspiracy, health care fraud conspiracy and money laundering. On or about March 22, 2017, the U.S. Attorney’s Office for the District of New Hampshire filed an indictment against a physician assistant, who served on our speaker bureau, charging him with violating the federal Anti-Kickback Statute and conspiring to violate the federal Anti-Kickback Statute in connection with payments received for serving as an Insys promotional speaker. The physician assistant pled not guilty. On or about October 20, 2017, a health care professional in Rhode Island, who served on our speaker bureau pled guilty to health care fraud and conspiracy to receive kickbacks in connection with payments of approximately $188,000 from us. Investigations of Former Employees . A number of our former employees have been charged in criminal proceedings related to our federal investigations and the following is certain information related thereto. On or about February 18, 2016, one of our former sales employees located in Alabama pled guilty to a conspiracy to violate the federal Anti-Kickback Statute in connection with the two convicted Alabama health care professionals mentioned above. On or about June 19, 2016, a former district sales manager in New York and a former sales representative in New Jersey were charged in a federal court in Manhattan, New York, with violating the federal Anti-Kickback Statute in connection with interacting with health care professionals who prescribed our product and served on our speaker bureau. On June 1, 2017, the former district sales manager was charged in a superseding indictment with additional charges of honest services wire fraud and aggravated identity theft in connection with falsifying sign-in sheets for our speaker programs. Both of these former employees in New York and New Jersey have pled not guilty. On or about December 8, 2016, the U.S. Attorney’s Office for the District of Massachusetts issued an indictment against six former employees, including Michael L. Babich, our former President, CEO and director, on charges including racketeering conspiracy, conspiracy to commit mail fraud, conspiracy to commit wire fraud, conspiracy to violate the Anti-Kickback Statute and forfeiture (the “Original Indictment”). On or about February 8, 2017, a former district sales manager in the Northeast was charged in federal court in New Haven, Connecticut, with violating the federal Anti-Kickback Statute in connection with interacting with health care professionals who prescribed our product and served on our speaker bureau. On April 5, 2017, the U.S. Attorney’s Office for the District of Massachusetts filed information charging a former prior authorization specialist and manager of our patient services hub with one count of wire fraud conspiracy; the former employee pled guilty to that information on June 19, 2017. On or about July 11, 2017, a former district sales manager pled guilty to conspiring to violate the federal Anti-Kickback Statute related to her activities in the Southern District of Alabama, as well as the Middle and Southern Districts of Florida, including in connection with the two convicted Alabama health care professionals mentioned above. On or about October 26, 2017, the U.S. Attorney’s Office for the District of Massachusetts issued a superseding indictment in connection with the Original Indictment and added charges against our former President, CEO and director, Dr. John N. Kapoor. After Dr. Kapoor’s indictment, he agreed to put his ownership in our common stock in a trust to be controlled independently, which was executed on February 27, 2018 and filed with the Securities and Exchange Commission on a Current Report of Form 8-K filed on February 28, 2018. Except as otherwise indicated, we understand that each of these indicted individuals have entered pleas of not guilty to the charges against them. Given the ongoing investigations related to our company and our current and former employees, as well as other individuals associated with our company, including health care professionals, it is possible that additional individual or company criminal charges and convictions and pleas could result from our ongoing federal and state government investigations and related proceedings and the foregoing disclosure and the disclosure below is merely intended to provide general insight into the comprehensive nature of the scope and breadth of investigations that are being conducted related to our company and is not, nor is it intended to be, an exhaustive listing of every charge, conviction or pleading in connection with our company. We continue to assess these matters to ensure we have an effective compliance program. Ongoing State Related Investigations . We have received CIDs or subpoenas, as the case may be, from at least each of the following state’s Office of the Attorney General (or similarly named and authorized office) which have ongoing investigations directed at our company: Arizona, Colorado, Florida, Kansas, Kentucky, Maryland, Minnesota, Missouri, New Jersey, New York, North Carolina, Pennsylvania, Rhode Island, Virginia and Washington. Moreover, we have received an administrative subpoena from the California Insurance Commissioner. In addition, we understand that numerous physicians practicing within several of the aforementioned states have received subpoenas from certain state Attorney General or Department of Justice offices in connection with interactions with us. Generally, these CIDs and subpoenas request documents regarding SUBSYS®, including our sales and marketing practices related to SUBSYS® in the applicable state, as well as our patient services hub. We are cooperating with each of these investigations and have produced documents in response to these CIDs, subpoenas and related requests for information from each office. Resolved State Related Investigations . Our company has resolved investigations conducted by certain states’ Office of the Attorney General (or similarly named and authorized office) as follows: In connection with the investigation by the ODOJ, we entered into a settlement agreement with the ODOJ, referred to as an AVC, and made monetary payments totaling approximately $1,100,000. The AVC requires us to maintain certain controls and processes around our promotional and sales activity related to SUBSYS® in Oregon. This AVC expressly provides that we do not admit any violation of law or regulation. This settlement was reached as a result of our cooperation with the ODOJ's investigation and after producing documents in response to certain CIDs and related requests for information from the ODOJ. All monetary payments in connection with this settlement were made prior to December 31, 2015. In connection with the investigation by the Illinois Office of the Attorney General, such office filed a complaint against us on behalf of the State of Illinois on August 25, 2016 in the Circuit Court of Cook County, Illinois, Chancery Division, asserting a claim for violation of the Illinois Consumer Fraud and Deceptive Business Practices Act in connection with the sales and marketing of SUBSYS®. On August 18, 2017, the Circuit Court of Cook County entered a Final Judgment and Consent Decree, which, among other things, provided for a monetary payment of $4,450,000 by Insys and requires us to maintain certain controls and processes around our promotional and sales activity related to SUBSYS® in Illinois. The Final Judgment and Consent Decree expressly provides that we do not admit any violation of law or regulation. All monetary payments in connection with this Final Judgment and Consent Decree were accrued in the consolidated balance sheet as of June 30, 2017 and the payments in connection with this settlement were made prior to September 30, 2017. In connection with the investigation by the State of New Hampshire, we entered into a settlement agreement with the State of New Hampshire referred to as an assurance of discontinuance, and made monetary payments totaling approximately $2,900,000 to the State of New Hampshire and a charitable contribution of $500,000 to be used by a New Hampshire charitable foundation in preventing or remediating problems related to abuse, misuse or misprescribing of opioid drugs. The assurance of discontinuance expressly provides that we do not admit any violation of law or regulation and requires us to maintain certain controls and processes around our promotional and sales activity related to SUBSYS® in New Hampshire. This settlement was reached as a result of our cooperation with the State of New Hampshire investigation and after producing documents in response to certain requests for information by the State of New Hampshire. These amounts were accrued in the consolidated balance sheet as of December 31, 2016 and the payments in connection with this settlement were made during the three months ended March 31, 2017. In connection with the investigation by the State of Massachusetts, we entered into a settlement with the State of Massachusetts, which was entered by the Superior Court of the Commonwealth of Massachusetts in a Final Judgment by Consent on October 5, 2017. The Final Judgment by Consent provided for a monetary payment of $500,000 and requires us to maintain certain controls and processes around our promotional and sales activity related to Massachusetts. The Final Judgment by Consent expressly provides that we do not admit any liability or wrongdoing. The amount of the monetary payment was accrued in the consolidated balance sheet as of September 30, 2017 and the payments in connection with this settlement were made after September 30, 2017. Ongoing Complaints filed in connection with State AG Investigations . Our company has several ongoing legal proceedings related to complaints filed in connection with investigations conducted by certain states’ Office of the Attorney General (or similarly named and authorized office) as follows: In connection with the investigation by the State of Arizona, on August 30, 2017, the Arizona Attorney General filed a complaint on behalf of the State of Arizona against us in the Maricopa County, Arizona Superior Court. The complaint asserts claims for violations of the Arizona Consumer Fraud Act in connection with the sales and marketing of SUBSYS® in Arizona and in connection with our patient services hub. The complaint seeks a permanent injunction preventing us from engaging in practices in violation of the Arizona Consumer Fraud Act, restitution to consumers and other persons, disgorgement of profits, civil penalties, and investigative costs. On or about November 10, 2017, we filed a motion to dismiss. On January 17, 2018, the Court dismissed, based upon preemption by the federal Sunshine Act, the State’s claim to the extent related to remedies that are based upon the payment and disclosure of speaker fees, but did not dismiss the rest of the complaint. The State filed a motion for leave to amend its complaint, which the Court granted. Our response to the amended complaint is due 10 days after the State files and serves its amended complaint. In connection with the investigation by the State of New Jersey, on October 5, 2017, the New Jersey Attorney General, on behalf of the State of New Jersey, and the Acting Director of the New Jersey Division of Consumer Affairs filed a complaint against us in the Superior Court of New Jersey, Chancery Division, Middlesex Vicinage. The complaint asserts claims for violations of the New Jersey Consumer Fraud Act and for violations of the New Jersey False Claims Act in connection with the sales and marketing of SUBSYS® in New Jersey and in connection with our patient services hub. The complaint seeks a permanent injunction preventing us from engaging in practices in violation of the New Jersey Consumer Fraud Act, disgorgement of profits, civil penalties, treble damages for alleged violations of the New Jersey False Claims Act, and costs and attorneys’ fees. On November 16, 2017, the New Jersey Attorney General filed an Amended Complaint, which we moved to dismiss on January 8, 2018. The New Jersey Attorney General’s response to our motion is due on March 28, 2018. On December 21, 2017, Attorney General of the State of North Carolina filed a complaint in Wake County, North Carolina Superior Court against us. The complaint asserts claims related to alleged violations of the North Carolina Consumer Protection Act. Our response to this complaint is due March 22, 2018. On February 1, 2018, the Attorney General of the State of New York, filed a complaint against us in the Supreme Court of the State of New York, County of New York. The complaint asserts claims related to alleged deceptive acts and practices. Our response to this complaint is due on April 4, 2018. On February 5, 2018, the Consumer Protection Division, Office of the Attorney General of Maryland, filed a petition to enforce an administrative subpoena against us. Our response to this petition is due on April 2, 2018. Multi-District Prescription Opioid Litigation . We have been named along with various other opioid manufacturers, opioid distributors, prescribers and others in complaints focused on the national opioid epidemic filed by various cities, counties, states, and third-party payers in many state and federal courts in Alabama, Connecticut, Florida, Georgia, Kentucky, Louisiana, Maryland, Michigan, Minnesota, New Hampshire, New Jersey, New Mexico, New York, Ohio, Oregon, Tennessee, Texas and West Virginia. We are involved in more than 100 of these cases, over 70 of which have been consolidated into multi-district litigation (No. 2804) in the Northern District of Ohio. The cases in the multi-district litigation are presently stayed while the Court seeks to facilitate a resolution. On March 1, 2018, the United States filed a statement of interest in the multi-district litigation, in which it requested a period of thirty days to evaluate whether to participate in the multi-district litigation proceedings at this stage. Congressional and Other Inquiries. Many federal agencies and branches are focused on the abuse of opioids in the United States and agencies such as the HHS have expressed their belief that the United States is in the midst of a prescription opioid abuse epidemic. Moreover, President Trump has declared the opioid crisis to be a public health emergency and has made it a priority to address this crisis. Members of our U.S. Congress have been conducting hearings and other inquiries into causes and solutions to the national opioid epidemic that have involved inquiries in our company’s practices. For example, on March 28, 2017, the Ranking Member of the Committee on Homeland Security and Governmental Affairs of the United States Senate distributed a letter to five manufacturers of opioid products, including us, requesting documents and information intended to aid such committee in understanding the challenges industry practices pose to efforts to curb opioid addiction and stem rising prescription drug costs for the federal government. This letter requests documents regarding our business, including the commercialization of SUBSYS®. This inquiry continues and has resulted in at least two reports that mention or address our company. We continue to cooperate with this inquiry. With the exception of the investigations by the ODOJ, the State of New Hampshire, the State of Illinois, the State of Massachusetts, and the DOJ, which we have quantified above, we believe a loss from an unfavorable outcome of these federal and state governmental proceedings is reasonably possible and an estimate of the amount or range of loss from an unfavorable outcome is not determinable at these stages. We believe we have meritorious legal positions and will continue to represent our interests vigorously in these matters. However, responding to government investigations has and could continue to burden us with substantial legal costs in connection with defending any claims raised. Any potential resulting fines, restitution, damages and penalties, settlement payments, pleas or exclusion from federal health care programs or other administrative actions, as well as any related actions brought by stockholders or other third parties, could have a material adverse effect on our financial position, results of operations or cash flows. Additionally, these matters could also have a negative impact on our reputation and divert the attention of our management from operating our business. Federal Securities Litigation and Derivative Complaints Federal Securities Litigation. On or about February 2, 2016, a complaint (captioned Richard Di Donato v. Insys Therapeutics, Inc., et al., Case 2:16-cv-00302-NVW) was filed in the United States District Court for the District of Arizona against us and certain of our current and former officers. The complaint was brought as a purported class action on behalf of purchasers of our common stock between March 3, 2015 and January 25, 2016. In general, the plaintiffs allege that the defendants violated the anti-fraud provisions of the federal securities laws by making materially false and misleading statements regarding our business, operations and compliance with laws during the class period, thereby artificially inflating the price of our common stock. On June 3, 2016, the Court appointed Clark Miller to serve as lead plaintiff. On June 24, 2016, the plaintiff filed a first amended complaint naming a former employee of Insys Therapeutics, Inc. as an additional defendant and extending the class period. On December 22, 2016, the plaintiff filed a second amended complaint, primarily to add allegations relating to an indictment of Michael L. Babich and certain of our former employees announced on December 8, 2016, and to extend the class period from August 12, 2014 through December 8, 2016. On January 12, 2017, the defendants moved to dismiss the second amended complaint. Oral arguments were heard by the Court on July 28, 2017 and the Court granted the motion in part and denied it in part. The plaintiff subsequently moved for leave to further amend the complaint, which we opposed. The parties await a ruling on the motion to amend. The plaintiff seeks unspecified monetary damages and other relief. We continue to vigorously defend this matter. On or about March 17, 2017, a complaint (captioned Kayd Currier v. Insys Therapeutics, Inc., et al., Case 1:17-cv-01954-PAC) was filed in United States District Court for the Southern District of New York against us and certain of our current and former officers. The complaint was brought as a purported class action on behalf of purchasers of our securities between February 23, 2016 and March 15, 2017. In general, the plaintiffs allege that the de

Note 8 - Equity

Note 8 - Equity	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Equity	8. Equity Preferred Stock In August 2014, we entered into a Rights Agreement with respect to a newly-designated Series A Junior Participating Preferred Stock. In connection with the Rights Agreement, our Board of Directors declared a dividend distribution of the right to purchase one one-hundredth of one share of our Series A Junior Participating Preferred Stock, par value $0.001 per share (a “Right”), for each outstanding share of common stock, par value $0.01 per share, held by the stockholders of the Company at the close of business on September 1, 2014 (the “Record Date”). Each Right entitles the registered holder to purchase from us one one-hundredth of a share of preferred stock (each, a “Preferred Share” and collectively, the “Preferred Shares”) at a price of $160 per one one-hundredth of a Preferred Share (the “Purchase Price”), subject to adjustment. Each one one-hundredth of a Preferred Share has the designations, powers, privileges, preferences, rights, qualifications, limitations and restrictions that are designed to make it the economic equivalent of one share of common stock. The Rights will not become exercisable until the earlier to occur of the close of business on (i) the tenth calendar day following acquisition by any person, entity or group of affiliated or associated persons of beneficial ownership of 15% or more of our outstanding shares of common stock (an “Acquiring Person”) or (ii) the tenth business day (or such later date as may be determined by action of the Board prior to such time as any person or entity becomes an Acquiring Person) following the date of commencement of, or the first announcement of, an intention to commence, a tender offer or exchange offer, the consummation of which would result in any person or entity or group of persons or entities acting in concert becoming an Acquiring Person (the earlier of such dates being called the “Distribution Date”). Until the Distribution Date, the Rights will be transferable with and only with our Common Shares. The Rights will expire ten years after the execution of the Rights Agreement unless the Rights are earlier redeemed or exchanged by us. Each Preferred Share is entitled to a minimum preferential quarterly dividend payment equal to the greater of $1.00 per share or 100 times the aggregate per share price of all cash and non-cash dividends declared per share of common stock. In the event of liquidation, the holders of the Preferred Shares would be entitled to a minimum preferential liquidation payment of $100 per share plus an amount equal to accrued and unpaid dividends and distributions thereon, provided that the Preferred Shares would be entitled to receive an aggregate amount per share equal to 100 times the aggregate amount to be distributed per share to holders of common stock. Each Preferred Share has 100 votes, voting together with the common stock. Common Stock On February 26, 2014, our Board of Directors approved a three-for-two stock split of our common stock effected through a stock dividend. The record date for the stock split was the close of business on March 17, 2014, with share distribution occurring on March 28, 2014. As a result of the dividend, shareholders received one additional share of Insys Therapeutics, Inc. common stock, par value $0.0002145, for each two shares they held as of the record date. All share and per share amounts were retroactively restated for the effects of this stock split. On May 6, 2014, our shareholders approved an amendment to our certificate of incorporation to increase the authorized shares of common stock from 50,000,000 to 100,000,000 and an amendment to increase the par value for our common stock to $0.01 per share. Our consolidated financial statements and notes herein were retroactively restated to reflect the impact of this amendment. On May 5, 2015, our Board of Directors approved a two-for-one stock split of our common stock effected through a stock dividend. The record date for the stock split was the close of business on May 26, 2015, with share distribution occurring on June 8, 2015. As a result of the dividend, shareholders received one additional share of Insys Therapeutics, Inc. common stock, par value $0.01, for each one share they held as of the record date. All share and per share amounts were retroactively restated for the effects of this stock split. Stock Repurchase Program On November 5, 2015, we announced a stock repurchase program. The stock repurchase program authorizes up to $50 million in repurchases of common stock, and any shares acquired will be retired as repurchased. This program was effective immediately and has no planned expiration date. The following table summarizes our share repurchase activity for our share repurchase program: Number of Shares Purchased Cost of Share Purchases Shares purchased at December 31, 2015 560,200 $ 16,459,000 Shares purchased during 2016 843,075 $ 16,099,000 Shares purchased at December 31, 2016 1,403,275 $ 32,558,000 Shares purchased during 2017 — — Shares purchased at December 31, 2017 1,403,275 $ 32,558,000 As of December 31, 2017, we had $17,442,000 remaining under this program.

Note 9 - Stock-based Compensati

Note 9 - Stock-based Compensation	12 Months Ended
	Dec. 31, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-based Compensation	9. Stock-based Compensation We currently have the following stock-based incentive plans: 2013 Employee Stock Purchase Plan The 2013 Employee Stock Purchase Plan (the “ESPP”) was adopted by our Board of Directors and approved by our stockholders, and became effective in connection with our initial public offering in May 2013. Under the terms of the ESPP, eligible employees are granted a purchase right to purchase shares of our common stock that cannot exceed 15% of their earnings, nor exceed the Board of Director defined limits on the number of our common shares that can be offered under the ESPP. The purchase right entitles the eligible employee to purchase shares at the lesser of an amount equal to 85% of the fair market value of the shares on the offering date or 85% of the fair market value of the shares on the purchase date. The ESPP authorized the issuance of 530,400 shares of common stock pursuant to purchase rights granted to our employees or to employees of any of our designated affiliates. The number of shares of common stock reserved for issuance will automatically increase on January 1 of each calendar year, from January 1, 2014 through January 1, 2023, by the least of (a) 1% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, (b) 600,000 shares (200,000 on a pre-split basis), or (c) a number determined by our Board of Directors that is less than (a) and (b). The ESPP is intended to qualify as an “employee stock purchase plan” within the meaning of Section 423 of the Internal Revenue Code of 1986, as amended (the “Code”). As of December 31, 2017, 1,667,773 shares of common stock have been purchased under the ESPP. 2013 Equity Incentive Plan The 2013 Equity Incentive Plan (the “2013 Plan”) is the successor to and continuation of the 2006 Equity Incentive Plan and the Insys Pharma, Inc., Amended and Restated Equity Incentive Plan. The 2013 Plan was adopted by our Board of Directors and approved by our stockholders, and became effective in connection with our initial public offering in May 2013. The 2013 Plan provides for the grant of stock awards, including stock options, restricted stock, stock appreciation rights, performance units, performance shares and other stock awards, to our employees, directors and consultants. The number of shares of common stock reserved for issuance will automatically increase on January 1 of each calendar year, from January 1, 2014 through January 1, 2023, by the lesser of (a) 4% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year; or (b) a number of shares of common stock that may be determined each year by our Board of Directors that is less than the preceding clause (a). As of December 31, 2017, options to purchase 6,332,415 shares of common stock were outstanding and 6,232,807 shares remained available for future grant. Amounts recognized in the consolidated statements of comprehensive income (loss) with respect to our stock-based compensation plans were as follows (in thousands): Years Ended December 31, 2017 2016 2015 Research and development $ 3,217 $ 3,931 $ 2,133 General and administrative 12,798 17,658 19,749 Total cost of stock-based compensation $ 16,015 $ 21,589 $ 21,882 Included in stock-based compensation for the years ended December 31, 2017, 2016 and 2015 was approximately $1,450,000, $3,878,000 and $4,867,000, respectively, of expense associated with the accelerated vesting of option awards related to terminated employees. The following table summarizes stock option activity during the year ended December 31, 2017: Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (in Aggregate Intrinsic Value (in millions) Outstanding as of December 31, 2014 7,707,162 $ 2.90 Granted 1,733,671 $ 14.57 Cancelled (695,061 ) $ 7.71 Exercised (1,607,683 ) $ 2.48 Outstanding as of December 31, 2015 7,138,089 $ 7.57 Granted 2,337,043 $ 14.86 Cancelled (1,536,538 ) $ 18.67 Exercised (637,721 ) $ 5.96 Outstanding as of December 31, 2016 7,300,873 $ 12.36 Granted 2,577,650 $ 10.73 Cancelled (2,059,826 ) $ 17.76 Expired (9,834 ) $ 20.13 Exercised (1,476,448 ) $ 3.08 $ 10.6 Outstanding as of December 31, 2017 6,332,415 $ 12.10 7.4 $ 12.0 Vested and exercisable as of December 31, 2017 3,499,957 $ 11.43 6.1 $ 10.2 The aggregate intrinsic value for stock options outstanding and exercisable is defined as the positive difference between the fair market value of our common stock and the exercise price of the stock options. As of December 31, 2017, we expect to recognize $21,748,000 of stock-based compensation for our outstanding options over a weighted-average period of 2.61 years. The total fair value of shares vested for the years ended December 31, 2017, 2016, and 2015 was $14,511,000, $19,970,000 and $25,392,000, respectively. Cash received from option exercises under all share-based payment arrangements for the years ended December 31, 2017, 2016 and 2015 was $4,545,000, $3,803,000 and $9,524,000, respectively. For the years ended December 31, 2016 and 2015, we recorded net reductions of $122,000 and $13,593,000 respectively, of our federal and state income tax liability, with an offsetting credit to additional paid-in capital resulting from the excess tax benefits related to exercised stock options. No such amounts were recognized during the year ended December 31, 2017, due to the implementation of ASU 2016-09. Stock Option Valuation Information The weighted-average assumptions used to estimate the fair value of employee stock options granted during the periods presented are as follows: 2017 2016 2015 Expected volatility 57.8 % 63.3 % 69.9 % Risk-free interest rate 2.2 % 1.6 % 1.9 % Expected term (in years) 6.9 7.0 7.0 Expected dividend yield 0.0 % 0.0 % 0.0 % For the years ended December 31, 2017, 2016, and 2015, the weighted-average estimated fair value per option granted was $6.32, $9.20 and $19.20, respectively. Restricted Stock Units From time to time we grant restricted stock units to certain employees and directors. Restricted stock units are valued at the closing market price of our common stock on the day of grant and the total value of the units is recognized as expense ratably over the vesting period of the grants. The following table summarizes restricted stock unit activity during the year ended December 31, 2017: Number of Shares Weighted Average Grant-Date Fair Value Per Unit Outstanding as of December 31, 2016 — $ — Granted 481,250 $ 10.74 Cancelled (85,350 ) $ 12.54 Exercised (14,000 ) $ 12.65 Outstanding as of December 31, 2017 381,900 $ 10.27 As of December 31, 2017, we expect to recognize $2,897,000 of stock-based compensation for outstanding restricted stock units over a weighted-average period of 2.06 years.

Note 10 - Income Taxes

Note 10 - Income Taxes	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	10. Income Taxes Income tax expense (benefit) consists of the following (in thousands): Years Ended December 31, 2017 2016 2015 Current income taxes: Federal $ (12,474 ) $ 5,916 $ 31,383 State and local 51 554 6,473 Total current income tax (12,423 ) 6,470 37,856 Deferred income taxes: Federal 20,178 (7,762 ) (3,759 ) State and local 3,065 2,126 (1,156 ) Total deferred income tax 23,243 (5,636 ) (4,915 ) Income tax expense $ 10,820 $ 834 $ 32,941 On December 22, 2017, the U.S. government enacted the Tax Cuts and Jobs Act. The 2017 Tax Act makes broad and complex changes to the U.S. tax code, including, but not limited to: reduces the federal statutory income tax rate from 35% to 21% effective January 1, 2018, eliminates the ability to carryback NOLs arising after 2017 and instead would permit such NOLs to be carried forward indefinitely, repeals the domestic production deduction, further limits deductions for executive compensation and legal settlements, accelerates expensing for capital expenditures, and reduces the orphan drug credit to 25% from 50% of qualified clinical testing expenses. We recognized, as a provisional estimate, a $7.5 million non-cash tax expense through income from continuing operations for the re-measurement of deferred tax assets and liabilities due to changes in tax laws included in the 2017 Tax Act. This re-measurement of deferred taxes had no impact on cash flows. On December 22, 2017, the SEC issued Staff Accounting Bulletin No. 118 Due to the timing of the enactment and the complexity involved in applying the provisions of the 2017 Tax Act, we have made reasonable estimates for certain effects of the 2017 Tax Act and recorded provisional amounts in our financial statements as of December 31, 2017. As we collect and prepare necessary data, and interpret the 2017 Tax Act and any additional guidance issued by the U.S. Treasury Department, the IRS, and other standard-setting bodies, we may make adjustments to the provisional amounts. Those adjustments may materially impact our provision for income taxes and effective tax rate in the period in which the adjustments are made. We expect to complete our accounting for the tax effects of the 2017 Tax Act in 2018. Estimates were used in determining the balance of deferred tax assets and liabilities subject to changes in tax laws included in the 2017 Tax Act. In addition, estimates were used in determining the timing of reversals of deferred tax assets and liabilities in assessing the ability to realize certain deferred tax assets, which impacted the valuation allowance adjustment we recorded as part of the effects of the 2017 Tax Act. Additional information and analysis is required to accurately determine the deferred tax assets and liabilities affected by the 2017 Tax Act, as well as determine the reversal pattern of such deferred tax assets and liabilities in assessing the ability to realize deferred tax assets. Deferred Income Taxes The tax effects of temporary differences and carry forwards that give rise to the deferred tax assets and liabilities are comprised of the following as of December 31 (in thousands): 2017 2016 Deferred income tax assets: NOLs and credits $ 38,858 $ 27,046 Start-up expenditures 1,480 2,604 Stock-based compensation 6,439 11,727 Allowances 931 1,264 Expenses currently not deductible for tax purposes 6,838 10,652 Deferred revenue 251 — Other 1,167 1,963 Gross deferred tax assets 55,964 55,256 Deferred income tax asset valuation allowance (50,339 ) (23,508 ) Deferred income tax assets 5,625 31,748 Deferred income tax liabilities: Federal impact of state taxes (643 ) (1,073 ) Property and equipment (4,058 ) (6,246 ) Prepaid expenses (924 ) (1,186 ) Net deferred income tax assets $ - $ 23,243 As of December 31, 2017, we had approximately $1.1 million of Federal NOLs and $236.6 million of state NOLs. A portion of both of these NOLs will begin to expire in 2018. As of December 31, 2017, we had approximately $11.4 million of Federal tax credits and $5.6 million of state tax credits. A portion of both the Federal and state tax credits will begin to expire in 2030. We record valuation allowances to reduce the book value of our deferred tax assets to amounts that are estimated on a more likely than not basis to be realized. In assessing the realization of deferred tax assets, we evaluate both positive and negative evidence with greater weight given to information that is objectively verifiable. Based on this evidence, we consider whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. We also consider the scheduled reversal of deferred tax liabilities, projected future taxable income or losses, and tax planning strategies in making this assessment. As a result of this evaluation, we increased the valuation allowance for deferred taxes by $26.8 million for the period ended December 31, 2017. The establishment of a valuation allowance does not impact cash, nor does it preclude us from using our tax credits, loss carryforwards and other deferred tax assets in the future. Effective Tax Rate Reconciliation: Our federal statutory tax rate is 35.0%, while our effective tax rate was (5.0)% for the year ended December 31, 2017, as set forth below: 2017 2016 2015 U.S. statutory tax rate 35.0 % 35.0 % 35.0 % Increase (reduction) of income taxes resulting from: State income taxes, net of federal benefit 0.7 % (0.1 )% 2.3 % Non-deductible litigation expense — 3.4 % 3.5 % Non-deductible and includible items (0.9 )% 7.5 % 0.7 % Non-deductible lobbying expense — 8.3 % — Research and other credits 1.1 % (63.5 )% (5.4 )% Uncertain tax positions (0.1 )% 4.2 % 2.7 % Domestic manufacturing deduction — (14.6 )% (3.0 )% Stock based compensation (1.3 )% 5.1 % 0.4 % Tax exempt interest income — (1.5 )% — Non-deductible settlement expenses (24.3 )% — — Adjustment of net deferred tax assets for U.S. tax reform (3.5 )% — — Other — 0.6 % — Change in valuation allowance (11.7 )% 25.5 % (0.1 )% Total provision for income taxes (5.0 )% 9.9 % 36.1 % The following is a reconciliation of the beginning and ending amounts of unrecognized tax benefits (in thousands): Years Ended December 31, 2017 2016 Beginning balance $ 9,800 $ 8,920 Additions based on current year's tax positions 555 758 Deductions based on prior year's tax positions (239 ) — Additions based on prior year's tax positions 18 122 Ending balance $ 10,134 $ 9,800 We establish reserves when it is more likely than not that we will not realize the full tax benefit of a position. We had a reserve of $10.1 million as of December 31, 2017, mostly related to tax credits of $2.8 million, state and local income tax filing positions of $5.4 million, and $1.9 million of other permanent differences. Although it is reasonably possible that certain unrecognized tax benefits may increase or decrease within the next twelve months due to tax examination changes, settlement activities, expirations of statutes of limitations, or the impact on recognition and measurement considerations related to the results of published tax cases or other similar activities, we do not anticipate any significant changes to unrecognized tax benefits over the next 12 months. Approximately $1.3 million of interest has been included in income taxes and accounted for on the balance sheet related to unrecognized tax positions as of December 31, 2017. We are currently under examination in the U.S. for tax years 2014 and 2015. Because of NOLs and research credit carryovers, substantially all of our tax years remain open to examination.

Note-11 - Net Income (Loss) per

Note-11 - Net Income (Loss) per Share	12 Months Ended
	Dec. 31, 2017
Earnings Per Share [Abstract]
Net Income (Loss) per Share	11. Net Income (Loss) per Share Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted average number of common shares outstanding during the period. The diluted income (loss) per share further includes any common shares available to be issued upon exercise of outstanding stock options if such inclusion would be dilutive. The following table sets forth the computation of basic and diluted net income (loss) per common share (in thousands, except per share amounts): Years Ended December 31, 2017 2016 2015 Historical net income (loss) per share - Basic Numerator: Net income (loss) $ (228,015 ) $ 7,590 $ 58,053 Denominator: Weighted average number of common shares outstanding 72,259,063 71,618,793 71,592,581 Basic net income (loss) per common share $ (3.16 ) $ 0.11 $ 0.81 Historical net income (loss) per share - Diluted Numerator: Net income (loss) $ (228,015 ) $ 7,590 $ 58,053 Denominator: Weighted average number of common shares outstanding 72,259,063 71,618,793 71,592,581 Effect of dilutive stock options — 2,527,125 4,115,070 Weighted average number of common shares outstanding 72,259,063 74,145,918 75,707,651 Diluted net income (loss) per common share $ (3.16 ) $ 0.10 $ 0.77 The calculation of diluted net income (loss) per common share excludes the effects of 1,677,040, 2,596,324 and 1,460,986 outstanding stock options for the years ended December 31, 2017, 2016, and 2015, respectively, as the impact of these options was anti-dilutive.

Note 12 - Product Lines, Concen

Note 12 - Product Lines, Concentration of Credit Risk and Significant Customers	12 Months Ended
	Dec. 31, 2017
Segment Reporting [Abstract]
Product Lines, Concentration of Credit Risk and Significant Customers	12. Product Lines, Concentration of Credit Risk and Significant Customers We are engaged in the business of developing and selling pharmaceutical products. In 2017, we have two product lines, SUBSYS® and SYNDROS®. Our CODM evaluates revenues based on product lines. The following tables summarize our net revenue by product line, as well as the percentages of revenue by route to market (in thousands): Net Revenue by Product Line Years Ended December 31, 2017 2016 2015 SUBSYS ® $ 139,250 $ 242,275 $ 329,040 SYNDROS ® 1,443 — — Dronabinol SG Capsule — — 1,283 Total net revenue $ 140,693 $ 242,275 $ 330,323 Percent of Revenue by Route to Market Years Ended December 31, 2017 2016 2015 Pharmaceutical wholesalers 63 % 67 % 95 % Specialty pharmaceutical retailers 37 % 33 % 5 % 100 % 100 % 100 % All our products are sold in the United States of America. Product shipments to our three largest pharmaceutical wholesaler customers accounted for 26%, 18% and 11% of total shipments and product shipments to two specialty pharmaceutical retailers accounted for 23% and 14% of total shipments for the year ended December 31, 2017. Product shipments to our four largest pharmaceutical wholesaler customers accounted for 17%, 16%, 15% and 14% of total shipments and product shipments to one specialty pharmaceutical retailer accounted for 32% of total shipments for the year ended December 31, 2016. Product shipments to our four largest pharmaceutical wholesaler customers accounted for 32%, 20%, 17% and 14% of total shipments for the year ended December 31, 2015. Three pharmaceutical wholesalers’ accounts receivable balances accounted for 44%, 18% and 10% of gross accounts receivable as of December 31, 2017, and two specialty pharmaceutical retailers’ accounts receivable balances accounted for 13% and 12% of gross accounts receivable as of December 31, 2017. Four pharmaceutical wholesalers’ accounts receivable balances accounted for 36%, 23%, 21% and 13% of gross accounts receivable as of December 31, 2016. Currently, for SUBSYS®, we use one vendor as our sole supplier of the active pharmaceutical ingredient in this product. Financial instruments that potentially subject us to concentrations of credit risk consist principally of cash and trade accounts receivable. We place our cash with high credit quality financial institutions and generally limit the amount of credit exposure to the amount of FDIC coverage. However, periodically during the year, we maintain cash in financial institutions in excess of the current FDIC insurance coverage limit of $250,000. We are exposed to credit risk in the event of a default by the institutions holding our cash to the extent recorded on the consolidated balance sheet. We perform ongoing credit evaluations of our customers’ financial condition but do not typically require collateral to support customer receivables. We established an allowance for doubtful accounts based upon factors surrounding the credit risk of specific customers, historical trends and other information.

Note 13 - Supplemental Financia

Note 13 - Supplemental Financial Information	12 Months Ended
	Dec. 31, 2017
Valuation And Qualifying Accounts [Abstract]
Supplemental Financial Information	13. Supplemental Financial Information A summary of additions and deductions related to the allowances for accounts receivable for the years ended December 31, 2017, 2016 and 2015 are as follows (in thousands): Balance at Beginning of Year Charged to Costs and Expenses Utilization Balance at End of Year Allowance for doubtful accounts: Year ended December 31, 2017 $ 685 $ — $ (685 ) $ — Year ended December 31, 2016 $ 811 $ (96 ) $ (30 ) $ 685 Year ended December 31, 2015 $ 398 $ 413 $ — $ 811 Allowance for sales wholesaler discounts, prompt pay discounts, stocking allowances, and chargebacks: Year ended December 31, 2017 $ 5,459 $ 14,525 $ (16,152 ) $ 3,832 Year ended December 31, 2016 $ 7,556 $ 27,968 $ (30,065 ) $ 5,459 Year ended December 31, 2015 $ 5,418 $ 38,036 $ (35,898 ) $ 7,556

Note 14 - Quarterly Results of

Note 14 - Quarterly Results of Operations (Unaudited)	12 Months Ended
	Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Information	14. Quarterly Results of Operations (Unaudited) The following table sets forth a summary of our unaudited quarterly operating results for each of the last eight quarters in the period ended December 31, 2017. We have derived this data from our unaudited consolidated interim financial statements that, in our opinion, have been prepared on substantially the same basis as the audited consolidated financial statements contained elsewhere in this report and include all normal recurring adjustments necessary for a fair presentation of the financial information for the periods presented. These unaudited quarterly results should be read in conjunction with our consolidated financial statements and notes thereto included elsewhere in this report. The operating results in any quarter are not necessarily indicative of the results that may be expected for any future period (in thousands, except per share data). Quarter Ended 12/31/17 9/30/17 6/30/17 3/31/17 Net revenue $ 31,485 $ 30,670 $ 42,576 $ 35,962 Gross profit (1) $ 26,874 $ 23,198 $ 38,655 $ 31,323 Net loss (2) (3) $ (46,987 ) $ (166,320 ) $ (8,184 ) $ (6,524 ) Net loss per common share: Basic $ (0.65 ) $ (2.30 ) $ (0.11 ) $ (0.09 ) Diluted $ (0.65 ) $ (2.30 ) $ (0.11 ) $ (0.09 ) Quarter Ended 12/31/16 9/30/16 6/30/16 3/31/16 Net revenue $ 54,860 $ 57,773 $ 69,221 $ 60,421 Gross profit (4) 45,055 53,096 62,948 55,783 Net income (loss) (5) (3,652 ) 2,925 6,027 2,290 Net income (loss) per common share: Basic $ (0.05 ) $ 0.04 $ 0.08 $ 0.03 Diluted $ (0.05 ) $ 0.04 $ 0.08 $ 0.03 (1) The fourth quarter of 2017 includes an allowance of $2,100,000 for excess and obsolete inventory as the result of a change in estimate. (2) The third quarter of 2017 includes an accrual of $150,000,000 related to the DOJ Investigation. (3) The fourth quarter of 2017 includes a provisional tax expense of $7,500,000 related to the 2017 Tax Act, and an increase in tax expense associated with the accrual of $22,600,000 related to the valuation allowance of deferred tax assets. (4) The fourth quarter of 2016 includes an allowance of $5,800,000 for excess and obsolete SUBSYS® inventory. (5) The fourth quarter of 2016 includes charges related to litigation award and settlements of $3,900,000.

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Insys Therapeutics, Inc. and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in the accompanying consolidated financial statements.
Reclassification	Reclassification Certain amounts in prior periods have been reclassified to conform to the current period presentation.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying values of certain of our financial instruments, including cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate their fair value due to the short-term nature of these financial instruments. FASB ASC No. 820, “Fair Value Measurement” defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. It also establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1: Observable inputs such as quoted prices in active markets; Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.
Revenue Recognition	Revenue Recognition We recognize revenue from the sale of SUBSYS® and SYNDROS®. Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred and title has passed, (iii) the price is fixed or determinable and (iv) collectability is reasonably assured. SUBSYS® was commercially launched in March 2012, and is available through a U.S. Food and Drug Administration (“FDA”) mandated Risk Evaluation and Mitigation program known as the Transmucosal Immediate Release Fentanyl program (“TIRF REMS”). We sell SUBSYS® in the United States to wholesale pharmaceutical distributors and directly to specialty retail pharmacies (collectively, our customers) subject to rights of return within a period beginning six months prior to, and ending 12 months following, product expiration. SUBSYS® currently has a shelf life of 36 or 48 months from the date of manufacture, depending on the manufacture date. We record revenue for SUBSYS® at the time the customer receives the shipment. SYNDROS® was commercially launched in July 2017. We sell SYNDROS® in the United States to wholesale pharmaceutical distributors and directly to retail pharmacies, collectively our customers, subject to rights of return within a period beginning six months prior to, and ending We recognize estimated product sales allowances as a reduction of product sales in the same period the related revenue is recognized. Product sales allowances are based on amounts owed or to be claimed on the related sales. These estimates take into consideration the terms of our agreements with customers and third-party payers and the levels of inventory within the distribution channels that may result in future discounts taken. In certain cases, such as patient assistance programs, we recognize the cost of patient discounts as a reduction of revenue based on estimated utilization. If actual future results vary, we may need to adjust these estimates, which could have an effect on product revenue in the period of adjustment. Our product sales allowances include: Product Returns. We allow customers to return product for credit within six months before and up to 12 months following its product expiration date. With respect to SUBSYS®, we have monitored actual return history since product launch, which provides us with a basis to reasonably estimate future product returns, taking into consideration the shelf life of product at the time of shipment, shipment and prescription trends, estimated distribution channel inventory levels, and consideration of the introduction of competitive products. Given the limited sales history of SYNDROS®, the Company currently cannot reliably estimate expected returns of the product at the time of shipment. Because of the shelf life of our products and our return policy of issuing credits on returned product that is within six months before and up to 12 months after its product expiration date, there may be a significant period of time between when the product is shipped and when we issue credits on returned product. Accordingly, we may have to adjust these estimates, which could have an effect on product sales and earnings in the period of adjustments. The allowance for product returns is included in accrued sales allowances. Wholesaler and Retailer Discounts. We offer discounts to certain wholesale distributors and specialty retailers based on contractually determined rates. We accrue the discount as a reduction of receivables due from the wholesalers and retailers upon shipment to the respective wholesale distributors and retail pharmacies. Prompt Pay Discounts. We offer cash discounts to our customers, generally 2.0% of the sales price, as an incentive for prompt payment. We account for cash discounts by reducing accounts receivable by the full amount of the discount. Stocking Allowances. We may offer discounts and extended payment terms, generally in the month of the initial commercial launch of a new product and on the first order made by certain wholesale distributors and retail pharmacies based on contractually determined rates. We accrue the discount as a reduction of receivables due from the wholesalers and retailers upon shipment to the respective wholesale distributors and retail pharmacies. Patient Discount Programs . We offer discount card programs to patients, in which patients receive discounts on their prescriptions that are reimbursed by us to the retailer. We estimate the total amount that will be redeemed based on a historical percentage of actual redemption applied to inventory in the distribution and retail channels. The allowance for patient discount programs is included in accrued sales allowances. Rebates. We participate in certain rebate programs, which provide discounted prescriptions to qualified insured patients. Under these rebate programs, we pay a rebate to the third-party administrator of the program, generally two to three months after the quarter in which prescriptions subject to the rebate are filled. We estimate and accrue these rebates based on current contract prices, historical and estimated future percentages of products sold to qualified patients and estimated levels of inventory in the distribution channel. The allowance for rebates is included in accrued sales allowances. Chargebacks. We provide discounts primarily to authorized users of the FSS of the General Services Administration under an FSS contract negotiated by the Department of Veterans Affairs and various organizations under Medicaid contracts and regulations. These entities purchase products from the wholesale distributors at a discounted price, and the wholesale distributors then charge back to us the difference between the current retail price and the price the entity paid for the product. We estimate and accrue chargebacks based on estimated wholesaler inventory levels, current contract prices and historical chargeback activity. Estimated chargebacks are recognized as a reduction of revenue in the same period the related revenue is recognized. The allowance for chargebacks is included as a reduction to accounts receivable. Dronabinol SG Capsule Our Dronabinol SG Capsule product was commercially launched in December 2011, and we sold Dronabinol SG Capsule exclusively to Mylan in the United States under a supply and distribution agreement. We discontinued sales of Dronabinol SG Capsule in 2015 and do not have any current plans to manufacture or market this product in the future.
Cash and Cash Equivalents	Cash and Cash Equivalents We consider all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The carrying value of those investments approximates their fair market value due to their short maturity and liquidity. Cash and cash equivalents include cash on hand and amounts on deposit with financial institutions, which at times may exceed current FDIC coverage limits of $250,000.
Short-Term and Long-Term Investments	Short-Term and Long-Term Investments Our policy for short-term and long-term investments is to establish a high-quality portfolio that preserves principal, meets liquidity needs, avoids inappropriate concentrations and delivers an appropriate yield in relationship to our investment guidelines and market conditions. Short-term and long-term investments consist of corporate, various government agency and municipal debt securities, as well as certificates of deposit that have maturity dates that are greater than 90 days. Certificates of deposit and commercial paper are carried at cost which approximates fair value. We classify our marketable securities as available-for-sale in accordance with FASB ASC Topic 320, “Investments — Debt and Equity Securities”. Available-for-sale securities are carried at fair value with unrealized gains and losses reported in stockholders’ equity, net of related tax effects. There were no reclassifications on available-for-sale securities during the year ended December 31, 2017. Reclassifications on available-for-sale securities were insignificant during the year ended December 31, 2016. A decline in the market value of any available-for-sale security below cost that is deemed to be other than temporary, results in impairment of the fair value of the investment. We did not have any realized gains or losses or decline in values judged to be other than temporary during the years ended December 31, 2017, 2016 and 2015. If we had realized gains and losses and declines in value judged to be other than temporary, we would have been required to include those changes in other expense in the consolidated statements of comprehensive income (loss). Premiums and discounts are amortized or accreted over the life of the related available-for-sale security. The cost of securities sold is calculated using the specific identification method. At December 31, 2017, our certificates of deposit and commercial paper as well as our marketable securities have been recorded at an estimated fair value of $4,499,000, $85,189,000 and $46,733,000 in cash and cash equivalents, short-term investments and long-term investments, respectively.
Accounts Receivable, Net	Accounts Receivable, Net Trade accounts receivable are recorded at the invoice amount net of allowances for wholesaler discounts, prompt pay discounts, stocking allowances, chargebacks and doubtful accounts. See “Revenue Recognition” above for a description of our wholesaler discounts, prompt pay discounts, stocking allowances and chargebacks. In the ordinary course of business, and consistent with industry practices, we may from time to time offer extended payment terms to our customers as an incentive for new product launches or in other circumstances. These extended payment terms do not represent a significant risk to the collectability of accounts receivable as of the period-end and are evaluated in accordance with ASC 605, “Revenue Recognition” as applicable. We evaluate the collectability of our accounts receivable based on a variety of factors including the length of time the receivables are past due, the financial health of the customer and historical experience. We write off accounts receivable against the allowance when a balance is determined to be uncollectable.
Inventories, Net	Inventories, Net Inventories consist of raw materials, work-in-process and finished product and are valued at the lower of cost (first-in, first-out cost method) or NRV. Non-current inventories are those that are not expected to be consumed or sold within 12 months of the balance sheet date. In evaluating whether inventory should be classified as current or noncurrent, management considers factors such as historical and anticipated future sales compared to quantities on hand and the remaining shelf life of products on hand. Inventory costs are capitalized prior to regulatory approval and product launch based on management’s judgment of probable future commercial use and net realizable value of the inventory. Such judgment incorporates our knowledge and best estimate of where the relevant product is in the regulatory process, our required investment in the product, market conditions, competing products and our economic expectations for the product post-approval relative to the risk of manufacturing the product prior to approval. In evaluating the recoverability of inventories produced in preparation for product launches, we consider the probability that revenue will be obtained from the future sale of the related inventory together with the status of the product within the regulatory approval process, as well as the market for the product in its current state. We could be required to permanently write down previously capitalized costs related to pre-approval or pre-launch inventory upon a change in such judgment, due to a denial or delay of approval by regulatory bodies, a delay in commercialization, or other potential factors including product expiration. Inventories are reviewed periodically for potential excess, dated or obsolete status. Management evaluates the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price we expect to obtain for products in their respective markets compared with historical cost, and the remaining shelf life of products on hand. During the year ended December 31, 2017, the Company refined its estimate for inventory obsolescence. The new estimate more closely aligns remaining product shelf life with anticipated future production and sales. The Company evaluated this change in accordance with ASC 250, “Accounting Changes and Error Corrections” and, accordingly, accounted for this change as a change in estimate. As a result of this change, the Company increased the inventory reserves by approximately $2.1 million during the year ended December 31, 2017.
Property and Equipment, Net	Property and Equipment, Net Property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives. Maintenance and repairs that do not extend the life of assets are charged to expense when incurred. When property and equipment is disposed of, the related costs and accumulated depreciation are removed from the accounts and any gain or loss is reported in the period the transaction takes place. Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted cash flows expected to be generated by the asset. If the carrying amount exceeds its estimated future undiscounted cash flows, an impairment charge is recognized by the amount by which the carrying amount exceeds the fair value of the asset.
Income Taxes	Income Taxes We account for our deferred income tax assets and liabilities based on differences between the financial reporting and tax bases of assets and liabilities, and net operating losses (“NOLs”) and other tax credit carry forwards. These items are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the period that includes the enactment date. We record a valuation allowance to reduce the deferred income tax assets to the amount that is more likely than not to be realized. In making such determinations, management considers all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operating results. We recognize a tax benefit from uncertain tax positions when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position. Our policy is to classify interest and penalties associated with income tax liabilities as income tax expense (benefit) in the consolidated statements of comprehensive income (loss).
Research and Development Expenses	Research and Development Expenses Research and development (“R&D”) costs are expensed when incurred. These costs consist of: (i) external research and development expenses incurred under agreements with third-party contract research organizations and investigative sites, third-party manufacturing organizations and consultants; (ii) employee-related expenses, which include salaries, benefits and stock-based compensation for the personnel involved in our preclinical and clinical drug development activities; (iii) facilities expense, depreciation and other allocated expenses; and (iv) equipment and laboratory supplies.
Advertising and Marketing	Advertising and Marketing Advertising and marketing costs are expensed as incurred. Advertising expense totaled $993,000, $1,572,000 and $1,166,000 for the years ended December 31, 2017, 2016 and 2015, respectively.
Legal Fees	Legal Fees Legal fees are expensed as incurred. Accordingly, we do not accrue for estimated future legal fees to be incurred in connection with litigation and other related legal matters. Legal expense is reported in general and administrative expenses, and totaled $20,328,000, $22,840,000 and $19,448,000 for the years ended December 31, 2017, 2016 and 2015, respectively.
Stock-Based Compensation Expenses	Stock-Based Compensation Expenses Stock-based compensation cost is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the service or vesting period, which is generally three to four years, on a straight-line basis. We account for forfeitures when they occur. We use the Black-Scholes option pricing model for estimating the grant date fair value of stock options using the following assumptions: • Volatility - Prior to our IPO, we did not have a reliable history of market prices for our common stock. Following our IPO, while we have an active trading market, we do not have sufficient historical data to accurately estimate volatility for the period equivalent to the expected term of the stock option grants. Accordingly, we estimate the expected stock price volatility for our common stock by taking the median historical stock price volatility for industry peers based on daily price observations over a period equivalent to the expected term of the stock option grants. We intend to incorporate the volatility of our own common stock share price in future periods as we begin to have sufficient historical data available. • Expected term - The expected term is based on a simplified method allowed by the SEC due to insufficient historical data, and • Risk-free rate - The risk-free interest rate for the expected term of the option is based on the average market rate on U.S. treasury securities in effect during the quarter in which the options were granted. • Dividends - The dividend yield assumption is based on our history and expectation of paying no dividends.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting period. On an on-going basis, we evaluate our estimates, including those related to revenue recognition (which is affected by prescriptions dispensed, wholesaler discounts, patient discount programs, rebates, and chargebacks), inventories, legal liabilities and settlements, stock-based compensation expense, and deferred tax valuation allowances. We base our estimates on historical experience and on various other assumptions that are believed by management to be reasonable under the circumstances. Actual results could materially differ from those estimates.
Segment Information	Segment Information FASB ASC No. 280, “Segment Reporting” establishes standards for reporting information about reportable segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group (“CODM”), in deciding how to allocate resources and in assessing performance. The CODM evaluates revenues and gross profits based on product lines and routes to market. Based on our integration and management strategies, we operate in a single reportable segment.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements Effective January 1, 2017, we adopted ASU No. 2016-09, “Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting”. Among other requirements, the new guidance requires all tax effects related to share-based payments at settlement (or expiration) to be recorded through the income statement. Previously, tax benefits in excess of compensation cost ("windfalls") were recorded in equity, and tax deficiencies ("shortfalls") were recorded in equity to the extent of previous windfalls, and then to the income statement. As required, this change was applied prospectively to all excess tax benefits and tax deficiencies resulting from settlements. Under the new guidance, the windfall tax benefit is to be recorded when it arises, subject to normal valuation allowance considerations. Excess tax benefits that were not previously recognized because the related tax deduction had not reduced current taxes payable were recorded through a cumulative effect adjustment as of the date of the adoption. As required, upon adoption, this change was applied on a modified retrospective basis, with a cumulative effect adjustment of a change in accounting principle of approximately $368,000 as a deferred tax asset with a corresponding valuation allowance of $368,000, which were offset in retained earnings. Additionally, our consolidated statement of cash flows now presents excess tax benefits as an operating activity, adjusted prospectively with no adjustments made to prior periods. Additionally, ASU No. 2016-09 addressed the presentation of employee taxes paid on the statement of cash flows. We are now required to present the cost of shares withheld from the employee to satisfy the employees’ income tax liability as a financing activity on the consolidated statement of cash flows rather than as an operating cash flow. This change was applied on a retrospective basis, as required, but did not impact the consolidated statement of cash flows for year ended December 31, 2017. ASU 2016-09 also permits entities to make an accounting policy election related to how forfeitures will impact the recognition of compensation cost for stock-based compensation to either estimate the total number of awards for which the requisite service period will not be rendered, as currently required, or to account for forfeitures as they occur. Upon adoption of ASU 2016-09, we elected to change our accounting policy to account for forfeitures as they occur. As required, this change was applied on a modified retrospective basis; however, as of December 31, 2016, we had estimated no forfeitures relating to the outstanding equity awards. As a result, no adjustment was required. Going forward, the adoption of ASU 2016-09 could cause volatility in the effective tax rate, as the excess tax benefits associated with the exercise of stock options could generate a significant discrete income tax benefit in a particular interim period, potentially creating volatility in net income and net income per share period-to-period and period-over-period. Effective January 1, 2017, we adopted ASU No. 2015-11, “Inventory (Topic 330): Simplifying the Measurement of Inventory”. Prior to January 1, 2017, we measured inventory at the lower of cost or market. This guidance requires us to measure inventory at the lower of cost and NRV, which eliminates the need to determine replacement cost and evaluate whether it is above the ceiling (NRV) or below the floor (NRV less a normal profit margin). The guidance defines NRV as the “estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation.” The adoption of this guidance did not have a material impact on our consolidated financial statements.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2017, the FASB issued ASU No. 2017-09, “Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting”, to provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. Specifically, the ASU requires modification accounting to a share-based payment award unless all of the following are the same immediately before and after the change: the award’s fair value; the award’s vesting conditions; and the award’s classification as an equity instrument or a liability instrument. The amendments should be applied prospectively to an award modified on or after the adoption date, and are effective for fiscal years beginning after December 15, 2017. We will adopt the new guidance on January 1, 2018. The adoption of this guidance will not have a material impact on our consolidated financial statements. The actual impact is subject to change prior to the filing of our 2018 first quarter results. In March 2017, the FASB issued ASU No. 2017-08, “Receivables—Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities”, to amend the amortization period for certain purchased callable debt securities held at a premium. The ASU shortens the amortization period for the premium to the earliest call date. Under current U.S. GAAP, entities generally amortize the premium as an adjustment of yield over the contractual life of the instrument. The amendments should be applied on a modified retrospective basis and are effective for fiscal years beginning after December 15, 2018. Early adoption is permitted, including adoption in an interim period. We are currently evaluating the impact of this amendment on our consolidated financial statements. In October 2016, the FASB issued ASU No. 2016-16, “Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory”, to improve the accounting for the income tax consequences of intra-entity transfers of assets other than inventory. Current U.S. GAAP prohibits the recognition of current and deferred income taxes for an intra-entity asset transfer until the asset has been sold to an outside party, which is an exception to the principle of comprehensive recognition of current and deferred income taxes in U.S. GAAP. The amendments in this update eliminate the exception for an intra-entity transfer of an asset other than inventory. The amendments should be applied on a modified retrospective transition basis, and are effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. We will adopt the new guidance on January 1, 2018. The adoption of this guidance will not have a material impact on our consolidated financial statements. The actual impact is subject to change prior to the filing of our 2018 first quarter results. In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments”. The amendments affect entities required to present a statement of cash flows and provides specific guidance on a variety of cash flow issues to reduce current and potential future diversity in practice. The amendments are effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The amendments should be applied using a retrospective transition method to each period presented. We will adopt the new guidance on January 1, 2018. The adoption of this guidance will not have a material impact on our consolidated financial statements. The actual impact is subject to change prior to the filing of our 2018 first quarter results. In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments”. The amendments affect entities holding financial assets and net investment in leases that are not accounted for at fair value through net income, and are effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years, and early adoption is permitted. ASU 2016-13 amends the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in the timelier recognition of losses. We are currently evaluating the impact of these amendments on our consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, “Leases: (Topic 842)”, to provide guidance on recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements, specifically differentiating between different types of leases. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from all leases. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee have not significantly changed from previous U.S. GAAP guidance. There continues to be a differentiation between finance leases and operating leases. However, the principal difference from previous guidance is that the lease assets and lease liabilities arising from operating leases should be recognized in the balance sheet. The accounting applied by a lessor is largely unchanged from that applied under previous U.S. GAAP guidance. The amendments will be effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, and early adoption is permitted. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. The modified retrospective approach includes a number of optional practical expedients that entities may elect to apply. These practical expedients relate to the identification and classification of leases that commenced before the effective date, initial direct costs for leases that commenced before the effective date, and the ability to use hindsight in evaluating lessee options to extend or terminate a lease or to purchase the underlying asset. An entity that elects to apply the practical expedients will, in effect, continue to account for leases that commence before the effective date in accordance with previous U.S. GAAP guidance unless the lease is modified, except that lessees are required to recognize a right-of-use asset and a lease liability for all operating leases at each reporting date based on the present value of the remaining minimum rental payments that were tracked and disclosed under previous U.S. GAAP guidance. While the effect of the pronouncement has not yet been quantified, the Company is continuing to evaluate the impact of recording the right-of-use-assets and liabilities on its financial position. The Company anticipates it will be required to record assets and liabilities for leases currently classified as operating leases. Commitments and Contingencies, In January 2016, the FASB issued ASU No. 2016-01, “Financial Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities”, which amended the Financial Instruments topic of the ASC to address certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. The amendments will be effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, and early adoption is not permitted. These amendments should be applied by means of a cumulative-effect adjustment to the balance sheet as of the beginning of the fiscal year of adoption. The amendments related to equity securities without readily determinable fair values (including disclosure requirements) should be applied prospectively to equity investments that exist as of the date of adoption. We will adopt the new guidance on January 1, 2018. The adoption of this guidance will not have a material impact on our consolidated financial statements. The actual impact is subject to change prior to the filing of our 2018 first quarter results. In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)”. The new standard aims to achieve a consistent application of revenue recognition within the United States, resulting in a single revenue model to be applied by reporting companies under U.S. GAAP. Under the new model, recognition of revenue occurs when a customer obtains control of promised goods or services in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, the new standard requires that reporting companies disclose the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The new standard is required to be applied either retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying it recognized at the date of initial application. In March 2016 and April 2016, the FASB issued ASU No. 2016-08 and ASU No. 2016-10, respectively, which further clarified the implementation guidance on principal versus agent considerations contained in ASU No. 2014-09 and the identification of performance obligations and licensing, respectively. In May 2016, the FASB issued ASU 2016-12, “Narrow-Scope Improvements and Practical Expedients”, which provides clarification on assessing the collectability criterion, presentation of sales taxes, measurement date for non-cash consideration and completed contracts at transition. These standards will be effective for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). The evaluation of the impact of ASU 2014-09, and the related ASUs, on existing contracts with our customers is complete. The change in accounting standard primarily affects our recognition of revenue from the sale of SYNDROS®, which was commercially launched in July 2017. Under current guidance, given the limited sales history of SYNDROS®, we defer recognition of revenue on product shipments of SYNDROS® until the right of return no longer exists, which occurs at the earlier of the time SYNDROS® units are sold to health care facilities or dispensed through patient prescription, or expiration of the right of return. We will adopt ASU 2014-09 effective January 1, 2018, using the modified retrospective transition method. The modified retrospective method requires that the cumulative effect of initially applying this guidance be recognized as an adjustment to the opening balance of retained earnings or accumulated deficit in the annual period that includes the date of initial application. We currently expect to record a decrease in accumulated deficit and a corresponding decrease to deferred revenue of approximately $0.8 million, net of tax, as of the adoption date. This cumulative adjustment is primarily attributable to the transition from deferring revenue until the right of return no longer exists to recognizing revenue when we conclude that it is probable that there is not a risk of significant revenue reversal in future periods. The actual impact is subject to change prior to the filing of our 2018 first quarter results. Additional quantitative and qualitative presentations and disclosures will be required on identified revenue streams and performance obligations. We have identified changes to our business processes and internal controls relating to review of variable consideration, contracts and disclosures, that are needed upon the adoption of the new guidance.

Note 3 - Short-term and Long-22

Note 3 - Short-term and Long-term Investments (Tables)	12 Months Ended
	Dec. 31, 2017
Schedule Of Investments [Abstract]
Summary of Investments	Investments consisted of the following at December 31, 2017 (in thousands): December 31, 2017 Cost Unrealized Gains Unrealized Losses Other- Than- Temporary Impairment Losses Fair Value Cash and Cash Equivalents Short-term Investments Long-term Investments Cash and cash equivalents $ 12,183 $ — $ — $ — $ 12,183 $ 12,183 $ — $ — Money market securities 15,317 — — — 15,317 15,317 — — Marketable securities: Certificates of deposit 18,447 — — — 18,447 — 7,474 10,973 Commercial paper 10,560 — — — 10,560 1,499 9,061 — Corporate securities 59,613 — (206 ) — 59,407 1,500 39,622 18,285 Federal agency securities 37,793 — (203 ) — 37,590 1,500 20,015 16,075 Municipal securities 10,446 — (29 ) — 10,417 — 9,017 1,400 Total marketable securities 136,859 — (438 ) — 136,421 4,499 85,189 46,733 $ 164,359 $ — $ (438 ) $ — $ 163,921 $ 31,999 $ 85,189 $ 46,733 Investments consisted of the following at December 31, 2016 (in thousands): December 31, 2016 Cost Unrealized Gains Unrealized Losses Other- Than- Temporary Impairment Losses Fair Value Cash and Cash Equivalents Short-term Investments Long-term Investments Cash and cash equivalents $ 49,331 $ — $ — $ — $ 49,331 $ 49,331 $ — $ — Money market securities 54,015 — — — 54,015 54,015 — — Marketable securities: Certificates of deposit 26,114 — — — 26,114 — 13,855 12,259 Commercial paper 1,485 — — — 1,485 — 1,485 — Corporate securities 39,562 — (135 ) — 39,427 500 25,681 13,246 Federal agency securities 30,660 4 (92 ) — 30,572 — 10,854 19,718 Municipal securities 35,811 2 (81 ) — 35,732 796 26,363 8,573 Total marketable securities 133,632 6 (308 ) — 133,330 1,296 78,238 53,796 $ 236,978 $ 6 $ (308 ) $ — $ 236,676 $ 104,642 $ 78,238 $ 53,796
Summary of Amortized Cost and Estimated Fair Value of Securities By Maturity	The amortized cost and estimated fair value of the marketable securities, by maturity, are shown below (in thousands): December 31, 2017 December 31, 2016 Amortized Cost Fair Value Amortized Cost Fair Value Marketable securities: Due in one year or less $ 90,071 $ 89,937 $ 80,092 $ 80,027 Due after one year through 5 years 46,788 46,484 53,540 53,303 Due after 5 years through 10 years — — — — Due after 10 years — — — — $ 136,859 $ 136,421 $ 133,632 $ 133,330
Summary of Gross Unrealized Losses and Fair Value of Investments	The following table shows the gross unrealized losses and the fair value of our investments, with unrealized losses that are not deemed to be other-than-temporarily impaired aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position (in thousands): December 31, 2017 December 31, 2016 Less Than 12 Months Greater Than 12 Months Less Than 12 Months Greater Than 12 Months Fair Value Unrealized Loss Fair Value Unrealized Loss Fair Value Unrealized Loss Fair Value Unrealized Loss Marketable securities: Corporate securities $ 245 $ (153 ) $ 7,839 $ (52 ) $ 38,027 $ (134 ) $ 401 $ (1 ) Federal agency securities 26,244 (89 ) 11,346 (114 ) 26,449 (91 ) 1,217 (1 ) Municipal securities 50,537 (18 ) 1,145 (12 ) 30,373 (81 ) 100 — $ 77,026 $ (260 ) $ 20,330 $ (178 ) $ 94,849 $ (306 ) $ 1,718 $ (2 )

Note 4 - Fair Value Measureme23

Note 4 - Fair Value Measurement (Tables)	12 Months Ended
	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Summary of Investments Measured at Fair Value on Recurring Basis	Our investments measured at fair value on a recurring basis subject to the disclosure requirements of ASC 820 at December 31, 2017 were as follows (in thousands): Fair Value Measurement at Reporting Date Total Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Marketable securities: Certificates of deposit $ 18,447 $ — $ 18,447 $ — Commercial paper 10,560 — 10,560 — Corporate securities 59,407 — 58,889 518 Federal agency securities 37,590 — 37,590 — Municipal securities 10,417 — 10,417 — Total assets measured at fair value $ 136,421 $ — $ 135,903 $ 518 Our investments measured at fair value on a recurring basis subject to the disclosure requirements of ASC 820 at December 31, 2016 were as follows (in thousands): Fair Value Measurement at Reporting Date Total Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Marketable securities: Certificates of deposit $ 26,114 $ — $ 26,114 $ — Commercial paper 1,485 — 1,485 — Corporate securities 39,427 — 38,927 500 Federal agency securities 30,572 — 30,572 — Municipal securities 35,732 — 35,732 — Total assets measured at fair value $ 133,330 $ — $ 132,830 $ 500
Summary of Additional Information about Assets Measured at Fair Value	The following table presents additional information about assets measured at fair value on a recurring basis and for which we utilize Level 3 inputs to determine fair value for the years ended December 31, 2017 and 2016 (in thousands): December 31, 2017 2016 Convertible stock Balance, beginning of period $ 500 $ — Change in fair value 18 — Purchases — 500 Balance, end of period $ 518 $ 500

Note 5 - Inventories, Net (Tabl

Note 5 - Inventories, Net (Tables)	12 Months Ended
	Dec. 31, 2017
Inventory Disclosure [Abstract]
Schedule of Components of Inventories Net of Allowances	The components of inventories, net of allowances, are as follows (in thousands): December 31, 2017 December 31, 2016 Finished goods $ 4,709 $ 8,408 Work-in-process 5,752 6,183 Raw materials and supplies 6,947 5,823 Total inventories 17,408 20,414 Plus: non-current raw materials and finished goods 826 6,257 $ 18,234 $ 26,671

Note 6 - Property and Equipme25

Note 6 - Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2017
Property Plant And Equipment [Abstract]
Components of Property and Equipment	Property and equipment are comprised of the following (in thousands): Estimated Useful Life As of December 31, (in years) 2017 2016 Computer equipment 3 — 7 $ 3,523 $ 3,462 Scientific equipment 3 — 10 14,962 12,930 Furniture 3 — 10 3,446 3,128 Manufacturing equipment 7 — 10 25,159 20,583 Leasehold improvements * 35,595 23,243 Less: accumulated depreciation and amortization (27,511 ) (20,174 ) Total fixed assets $ 55,174 $ 43,172 * The estimated useful life of the leasehold improvements is the lesser of the lease term or the estimated useful life.

Note 7 - Commitments and Cont26

Note 7 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2017
Commitments And Contingencies Disclosure [Abstract]
Summary of Future Minimum Commitments for Operating Leases	Future minimum commitments for these operating leases in place as of December 31, 2017, with a remaining non-cancelable lease term in excess of one year, are as follows (in thousands): Years ending December 31, 2018 $ 3,310 2019 3,405 2020 3,495 2021 2,526 2022 1,283 Thereafter 13,146 Total $ 27,165
Summary of Aggregate Minimum Purchase Commitments	The following table sets forth our aggregate minimum purchase commitments with Renaissance and Aptar under these agreements (in thousands): Years ending December 31, 2018 $ 5,500 2019 6,000 2020 6,000 2021 2,000 2022 — Thereafter — Total $ 19,500

Note 8 - Equity (Tables)

Note 8 - Equity (Tables)	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Summary of Share Repurchase Activity	The following table summarizes our share repurchase activity for our share repurchase program: Number of Shares Purchased Cost of Share Purchases Shares purchased at December 31, 2015 560,200 $ 16,459,000 Shares purchased during 2016 843,075 $ 16,099,000 Shares purchased at December 31, 2016 1,403,275 $ 32,558,000 Shares purchased during 2017 — — Shares purchased at December 31, 2017 1,403,275 $ 32,558,000

Note 9 - Stock-based Compensa28

Note 9 - Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Amounts Recognized in Condensed Consolidated Statements of Income and Comprehensive Income (Loss) with Respect to Stock-Based Compensation Plans	Amounts recognized in the consolidated statements of comprehensive income (loss) with respect to our stock-based compensation plans were as follows (in thousands): Years Ended December 31, 2017 2016 2015 Research and development $ 3,217 $ 3,931 $ 2,133 General and administrative 12,798 17,658 19,749 Total cost of stock-based compensation $ 16,015 $ 21,589 $ 21,882
Summary of Stock Option Activity	The following table summarizes stock option activity during the year ended December 31, 2017: Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (in Aggregate Intrinsic Value (in millions) Outstanding as of December 31, 2014 7,707,162 $ 2.90 Granted 1,733,671 $ 14.57 Cancelled (695,061 ) $ 7.71 Exercised (1,607,683 ) $ 2.48 Outstanding as of December 31, 2015 7,138,089 $ 7.57 Granted 2,337,043 $ 14.86 Cancelled (1,536,538 ) $ 18.67 Exercised (637,721 ) $ 5.96 Outstanding as of December 31, 2016 7,300,873 $ 12.36 Granted 2,577,650 $ 10.73 Cancelled (2,059,826 ) $ 17.76 Expired (9,834 ) $ 20.13 Exercised (1,476,448 ) $ 3.08 $ 10.6 Outstanding as of December 31, 2017 6,332,415 $ 12.10 7.4 $ 12.0 Vested and exercisable as of December 31, 2017 3,499,957 $ 11.43 6.1 $ 10.2
Summary of Weighted-Average Assumptions used to Estimate Fair Value of Employee Stock Options	The weighted-average assumptions used to estimate the fair value of employee stock options granted during the periods presented are as follows: 2017 2016 2015 Expected volatility 57.8 % 63.3 % 69.9 % Risk-free interest rate 2.2 % 1.6 % 1.9 % Expected term (in years) 6.9 7.0 7.0 Expected dividend yield 0.0 % 0.0 % 0.0 %
Summary of Restricted Stock Unit Activity	The following table summarizes restricted stock unit activity during the year ended December 31, 2017: Number of Shares Weighted Average Grant-Date Fair Value Per Unit Outstanding as of December 31, 2016 — $ — Granted 481,250 $ 10.74 Cancelled (85,350 ) $ 12.54 Exercised (14,000 ) $ 12.65 Outstanding as of December 31, 2017 381,900 $ 10.27

Note 10 - Income Taxes (Tables)

Note 10 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income Tax Expense (Benefit)	Income tax expense (benefit) consists of the following (in thousands): Years Ended December 31, 2017 2016 2015 Current income taxes: Federal $ (12,474 ) $ 5,916 $ 31,383 State and local 51 554 6,473 Total current income tax (12,423 ) 6,470 37,856 Deferred income taxes: Federal 20,178 (7,762 ) (3,759 ) State and local 3,065 2,126 (1,156 ) Total deferred income tax 23,243 (5,636 ) (4,915 ) Income tax expense $ 10,820 $ 834 $ 32,941
Deferred Tax Assets	The tax effects of temporary differences and carry forwards that give rise to the deferred tax assets and liabilities are comprised of the following as of December 31 (in thousands): 2017 2016 Deferred income tax assets: NOLs and credits $ 38,858 $ 27,046 Start-up expenditures 1,480 2,604 Stock-based compensation 6,439 11,727 Allowances 931 1,264 Expenses currently not deductible for tax purposes 6,838 10,652 Deferred revenue 251 — Other 1,167 1,963 Gross deferred tax assets 55,964 55,256 Deferred income tax asset valuation allowance (50,339 ) (23,508 ) Deferred income tax assets 5,625 31,748 Deferred income tax liabilities: Federal impact of state taxes (643 ) (1,073 ) Property and equipment (4,058 ) (6,246 ) Prepaid expenses (924 ) (1,186 ) Net deferred income tax assets $ - $ 23,243
Effective Tax Rate Reconciliation	Our federal statutory tax rate is 35.0%, while our effective tax rate was (5.0)% for the year ended December 31, 2017, as set forth below: 2017 2016 2015 U.S. statutory tax rate 35.0 % 35.0 % 35.0 % Increase (reduction) of income taxes resulting from: State income taxes, net of federal benefit 0.7 % (0.1 )% 2.3 % Non-deductible litigation expense — 3.4 % 3.5 % Non-deductible and includible items (0.9 )% 7.5 % 0.7 % Non-deductible lobbying expense — 8.3 % — Research and other credits 1.1 % (63.5 )% (5.4 )% Uncertain tax positions (0.1 )% 4.2 % 2.7 % Domestic manufacturing deduction — (14.6 )% (3.0 )% Stock based compensation (1.3 )% 5.1 % 0.4 % Tax exempt interest income — (1.5 )% — Non-deductible settlement expenses (24.3 )% — — Adjustment of net deferred tax assets for U.S. tax reform (3.5 )% — — Other — 0.6 % — Change in valuation allowance (11.7 )% 25.5 % (0.1 )% Total provision for income taxes (5.0 )% 9.9 % 36.1 %
Beginning and Ending Amounts of Unrecognized Tax Benefits	The following is a reconciliation of the beginning and ending amounts of unrecognized tax benefits (in thousands): Years Ended December 31, 2017 2016 Beginning balance $ 9,800 $ 8,920 Additions based on current year's tax positions 555 758 Deductions based on prior year's tax positions (239 ) — Additions based on prior year's tax positions 18 122 Ending balance $ 10,134 $ 9,800

Note-11 - Net Income (Loss) p30

Note-11 - Net Income (Loss) per Share (Tables)	12 Months Ended
	Dec. 31, 2017
Earnings Per Share [Abstract]
Schedule of Computation of Basic and Diluted Net Income (Loss) Per Common Share	The following table sets forth the computation of basic and diluted net income (loss) per common share (in thousands, except per share amounts): Years Ended December 31, 2017 2016 2015 Historical net income (loss) per share - Basic Numerator: Net income (loss) $ (228,015 ) $ 7,590 $ 58,053 Denominator: Weighted average number of common shares outstanding 72,259,063 71,618,793 71,592,581 Basic net income (loss) per common share $ (3.16 ) $ 0.11 $ 0.81 Historical net income (loss) per share - Diluted Numerator: Net income (loss) $ (228,015 ) $ 7,590 $ 58,053 Denominator: Weighted average number of common shares outstanding 72,259,063 71,618,793 71,592,581 Effect of dilutive stock options — 2,527,125 4,115,070 Weighted average number of common shares outstanding 72,259,063 74,145,918 75,707,651 Diluted net income (loss) per common share $ (3.16 ) $ 0.10 $ 0.77

Note 12 - Product Lines, Conc31

Note 12 - Product Lines, Concentration of Credit Risk and Significant Customers (Tables)	12 Months Ended
	Dec. 31, 2017
Segment Reporting [Abstract]
Summary of Net Revenue by Product Line	The following tables summarize our net revenue by product line, as well as the percentages of revenue by route to market (in thousands): Net Revenue by Product Line Years Ended December 31, 2017 2016 2015 SUBSYS ® $ 139,250 $ 242,275 $ 329,040 SYNDROS ® 1,443 — — Dronabinol SG Capsule — — 1,283 Total net revenue $ 140,693 $ 242,275 $ 330,323
Percentage of Revenue by Route to Market	Percent of Revenue by Route to Market Years Ended December 31, 2017 2016 2015 Pharmaceutical wholesalers 63 % 67 % 95 % Specialty pharmaceutical retailers 37 % 33 % 5 % 100 % 100 % 100 %

Note 13 - Supplemental Financ32

Note 13 - Supplemental Financial Information (Tables)	12 Months Ended
	Dec. 31, 2017
Valuation And Qualifying Accounts [Abstract]
Allowances for Accounts Receivables	A summary of additions and deductions related to the allowances for accounts receivable for the years ended December 31, 2017, 2016 and 2015 are as follows (in thousands): Balance at Beginning of Year Charged to Costs and Expenses Utilization Balance at End of Year Allowance for doubtful accounts: Year ended December 31, 2017 $ 685 $ — $ (685 ) $ — Year ended December 31, 2016 $ 811 $ (96 ) $ (30 ) $ 685 Year ended December 31, 2015 $ 398 $ 413 $ — $ 811 Allowance for sales wholesaler discounts, prompt pay discounts, stocking allowances, and chargebacks: Year ended December 31, 2017 $ 5,459 $ 14,525 $ (16,152 ) $ 3,832 Year ended December 31, 2016 $ 7,556 $ 27,968 $ (30,065 ) $ 5,459 Year ended December 31, 2015 $ 5,418 $ 38,036 $ (35,898 ) $ 7,556

Note 14 - Quarterly Results o33

Note 14 - Quarterly Results of Operations (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Results of Operations	Quarter Ended 12/31/17 9/30/17 6/30/17 3/31/17 Net revenue $ 31,485 $ 30,670 $ 42,576 $ 35,962 Gross profit (1) $ 26,874 $ 23,198 $ 38,655 $ 31,323 Net loss (2) (3) $ (46,987 ) $ (166,320 ) $ (8,184 ) $ (6,524 ) Net loss per common share: Basic $ (0.65 ) $ (2.30 ) $ (0.11 ) $ (0.09 ) Diluted $ (0.65 ) $ (2.30 ) $ (0.11 ) $ (0.09 ) Quarter Ended 12/31/16 9/30/16 6/30/16 3/31/16 Net revenue $ 54,860 $ 57,773 $ 69,221 $ 60,421 Gross profit (4) 45,055 53,096 62,948 55,783 Net income (loss) (5) (3,652 ) 2,925 6,027 2,290 Net income (loss) per common share: Basic $ (0.05 ) $ 0.04 $ 0.08 $ 0.03 Diluted $ (0.05 ) $ 0.04 $ 0.08 $ 0.03 (1) The fourth quarter of 2017 includes an allowance of $2,100,000 for excess and obsolete inventory as the result of a change in estimate. (2) The third quarter of 2017 includes an accrual of $150,000,000 related to the DOJ Investigation. (3) The fourth quarter of 2017 includes a provisional tax expense of $7,500,000 related to the 2017 Tax Act, and an increase in tax expense associated with the accrual of $22,600,000 related to the valuation allowance of deferred tax assets. (4) The fourth quarter of 2016 includes an allowance of $5,800,000 for excess and obsolete SUBSYS® inventory. (5) The fourth quarter of 2016 includes charges related to litigation award and settlements of $3,900,000.

Note 1 - Nature of Business (De

Note 1 - Nature of Business (Details Textual)	12 Months Ended
	Dec. 31, 2017ProductLine
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Number of Product Lines	2

Note 2 - Significant Accounti35

Note 2 - Significant Accounting Policies (Details Textual)	Jan. 01, 2018USD ($)	Dec. 31, 2017USD ($)Segmentshares	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Significant Accounting Policies [Line Items]
Cash, FDIC Insured Amount		$ 250,000
Realized Investment Gains (Losses)		0	$ 0	$ 0
Reclassifications on available-for-sale securities		0
Investment Owned, at Fair Value		163,921,000	236,676,000
Increase (decrease) in inventory valuation reserves		6,186,000	7,397,000	(336,000)
Advertising Expense		993,000	1,572,000	1,166,000
Legal Fees		$ 20,328,000	$ 22,840,000	$ 19,448,000
Number of reportable segment | Segment		1
Deferred revenue		$ 1,109,000
Subsequent Event [Member]
Significant Accounting Policies [Line Items]
Deferred revenue	$ (800,000)
ASU No. 2016-09 [Member]
Significant Accounting Policies [Line Items]
Estimated forfeitures relating to outstanding equity awards | shares		0
Adjustment to forfeitures relating to outstanding equity awards		$ 0
ASU No. 2016-09 [Member] | Deferred Tax Asset [Member]
Significant Accounting Policies [Line Items]
Cumulative effect adjustment of change in accounting principle		368,000
ASU No. 2016-09 [Member] | Deferred Tax Asset Valuation Allowance [Member]
Significant Accounting Policies [Line Items]
Cumulative effect adjustment of change in accounting principle		368,000
ASU 2014-09 [Member] | Subsequent Event [Member] | Retained Earnings [Member]
Significant Accounting Policies [Line Items]
Cumulative effect adjustment of change in accounting principle	$ 800,000
Inventory Valuation and Obsolescence [Member]
Significant Accounting Policies [Line Items]
Increase (decrease) in inventory valuation reserves		2,100,000
Cash and Cash Equivalents [Member]
Significant Accounting Policies [Line Items]
Investment Owned, at Fair Value		4,499,000
Short-term Investments [Member]
Significant Accounting Policies [Line Items]
Investment Owned, at Fair Value		85,189,000
Other Long-term Investments [Member]
Significant Accounting Policies [Line Items]
Investment Owned, at Fair Value		$ 46,733,000
Minimum [Member]
Significant Accounting Policies [Line Items]
Stock-based compensation award, vesting period		3 years
Maximum [Member]
Significant Accounting Policies [Line Items]
Stock-based compensation award, vesting period		4 years
SUBSYS [Member]
Significant Accounting Policies [Line Items]
Product Return, Period Prior to Expiration		6 months
Product Return, Period After Expiration		12 months
Cash Discount, Percent		2.00%
SUBSYS [Member] | Minimum [Member]
Significant Accounting Policies [Line Items]
Shelf Life of Product from Date of Manufacture		36 months
SUBSYS [Member] | Maximum [Member]
Significant Accounting Policies [Line Items]
Shelf Life of Product from Date of Manufacture		48 months
SYNDROS [Member]
Significant Accounting Policies [Line Items]
Product Return, Period Prior to Expiration		6 months
Product Return, Period After Expiration		12 months
SYNDROS [Member] | Minimum [Member]
Significant Accounting Policies [Line Items]
Shelf Life of Product from Date of Manufacture		24 months
SYNDROS [Member] | Maximum [Member]
Significant Accounting Policies [Line Items]
Shelf Life of Product from Date of Manufacture		36 months

Note 3 - Short-term and Long-36

Note 3 - Short-term and Long-term Investments - Summary of Investments (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Schedule Of Investments [Line Items]
Cost	$ 164,359	$ 236,978
Unrealized Gains		6
Unrealized Losses	(438)	(308)
Fair Value	163,921	236,676
Cash and Cash Equivalents	31,999	104,642	$ 79,515	$ 58,106
Short-term Investments	85,189	78,238
Long-term Investments	46,733	53,796
Commercial Paper [Member]
Schedule Of Investments [Line Items]
Cost	10,560	1,485
Fair Value	10,560	1,485
Cash and Cash Equivalents	1,499
Short-term Investments	9,061	1,485
Corporate Securities [Member]
Schedule Of Investments [Line Items]
Cost	59,613	39,562
Unrealized Losses	(206)	(135)
Fair Value	59,407	39,427
Cash and Cash Equivalents	1,500	500
Short-term Investments	39,622	25,681
Long-term Investments	18,285	13,246
Federal Agency Securities [Member]
Schedule Of Investments [Line Items]
Cost	37,793	30,660
Unrealized Gains		4
Unrealized Losses	(203)	(92)
Fair Value	37,590	30,572
Cash and Cash Equivalents	1,500
Short-term Investments	20,015	10,854
Long-term Investments	16,075	19,718
Municipal Securities [Member]
Schedule Of Investments [Line Items]
Cost	10,446	35,811
Unrealized Gains		2
Unrealized Losses	(29)	(81)
Fair Value	10,417	35,732
Cash and Cash Equivalents		796
Short-term Investments	9,017	26,363
Long-term Investments	1,400	8,573
Marketable Securities [Member]
Schedule Of Investments [Line Items]
Cost	136,859	133,632
Unrealized Gains		6
Unrealized Losses	(438)	(308)
Fair Value	136,421	133,330
Cash and Cash Equivalents	4,499	1,296
Short-term Investments	85,189	78,238
Long-term Investments	46,733	53,796
Cash and Cash Equivalents [Member]
Schedule Of Investments [Line Items]
Cost	12,183	49,331
Fair Value	12,183	49,331
Cash and Cash Equivalents	12,183	49,331
Money Market Securities [Member]
Schedule Of Investments [Line Items]
Cost	15,317	54,015
Fair Value	15,317	54,015
Cash and Cash Equivalents	15,317	54,015
Certificates of Deposit [Member]
Schedule Of Investments [Line Items]
Cost	18,447	26,114
Fair Value	18,447	26,114
Short-term Investments	7,474	13,855
Long-term Investments	$ 10,973	$ 12,259

Note 3 - Short-term and Long-37

Note 3 - Short-term and Long-term Investments - Summary of Amortized Cost and Estimated Fair Value of Securities By Maturity (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Marketable securities:
Due in one year or less, Amortized Cost	$ 90,071	$ 80,092
Due after one year through 5 years, Amortized Cost	46,788	53,540
Total, Amortized Cost	136,859	133,632
Due in one year or less, Fair Value	89,937	80,027
Due after one year through 5 years, Fair Value	46,484	53,303
Total, Fair value	$ 136,421	$ 133,330

Note 3 - Short-term and Long-38

Note 3 - Short-term and Long-term Investments - Summary of Gross Unrealized Losses and Fair Value of Investments (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Marketable securities:
Less Than 12 Months Fair Value	$ 77,026	$ 94,849
Less Than 12 Months Unrealized Loss	(260)	(306)
Greater Than 12 Months Fair Value	20,330	1,718
Greater Than 12 Months Unrealized Loss	(178)	(2)
Corporate Bond Securities [Member]
Marketable securities:
Less Than 12 Months Fair Value	245	38,027
Less Than 12 Months Unrealized Loss	(153)	(134)
Greater Than 12 Months Fair Value	7,839	401
Greater Than 12 Months Unrealized Loss	(52)	(1)
Federal Agency Securities [Member]
Marketable securities:
Less Than 12 Months Fair Value	26,244	26,449
Less Than 12 Months Unrealized Loss	(89)	(91)
Greater Than 12 Months Fair Value	11,346	1,217
Greater Than 12 Months Unrealized Loss	(114)	(1)
Municipal Securities [Member]
Marketable securities:
Less Than 12 Months Fair Value	50,537	30,373
Less Than 12 Months Unrealized Loss	(18)	(81)
Greater Than 12 Months Fair Value	1,145	$ 100
Greater Than 12 Months Unrealized Loss	$ (12)

Note 4 - Fair Value Measureme39

Note 4 - Fair Value Measurement (Details Textual) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Fair Value Disclosures [Abstract]
Assets measured at fair value on nonrecurring basis	$ 0	$ 0
Liabilities measured at fair value on nonrecurring basis	$ 0	$ 0

Note 4 - Fair Value Measureme40

Note 4 - Fair Value Measurement - Summary of Investments Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Available-for-sale securities	$ 136,421	$ 133,330
Significant Other Observable Inputs (Level 2) [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Available-for-sale securities	135,903	132,830
Significant Unobservable Inputs (Level 3) [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Available-for-sale securities	518	500
Certificates of Deposit [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Available-for-sale securities	18,447	26,114
Certificates of Deposit [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Available-for-sale securities	18,447	26,114
Commercial Paper [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Available-for-sale securities	10,560	1,485
Commercial Paper [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Available-for-sale securities	10,560	1,485
Corporate Securities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Available-for-sale securities	59,407	39,427
Corporate Securities [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Available-for-sale securities	58,889	38,927
Corporate Securities [Member] | Significant Unobservable Inputs (Level 3) [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Available-for-sale securities	518	500
Federal Agency Securities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Available-for-sale securities	37,590	30,572
Federal Agency Securities [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Available-for-sale securities	37,590	30,572
Municipal Securities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Available-for-sale securities	10,417	35,732
Municipal Securities [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Available-for-sale securities	$ 10,417	$ 35,732

Note 4 - Fair Value Measureme41

Note 4 - Fair Value Measurement - Summary of Additional Information about Assets Measured at Fair Value (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Fair Value Disclosures [Abstract]
Balance, beginning of period	$ 500
Change in fair value	18
Purchases		$ 500
Balance, end of period	$ 518	$ 500

Note 5 - Inventories - Schedule

Note 5 - Inventories - Schedule of Components of Inventories Net of Allowances (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Finished goods	$ 4,709	$ 8,408
Work-in-process	5,752	6,183
Raw materials and supplies	6,947	5,823
Total inventories	17,408	20,414
Plus: non-current raw materials and finished goods	826	6,257
Inventories, net	$ 18,234	$ 26,671

Note 5 - Inventories (Details T

Note 5 - Inventories (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Inventory [Line Items]
Deferred cost of revenue	$ 59,000	$ 0
Inventory Valuation Reserves	13,664,000	7,478,000
Increase (decrease) in inventory valuation reserves	6,186,000	$ 7,397,000	$ (336,000)
Inventory Valuation and Obsolescence [Member]
Inventory [Line Items]
Increase (decrease) in inventory valuation reserves	$ 2,100,000

Note 6 - Property and Equipme44

Note 6 - Property and Equipment - Components of Property and Equipment (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2016	Dec. 31, 2017
Property Plant And Equipment [Line Items]
Less: accumulated depreciation and amortization		$ (20,174)	$ (27,511)
Total fixed assets		43,172	55,174
Computer Equipment [Member]
Property Plant And Equipment [Line Items]
Property, Plant and Equipment, gross		$ 3,462	3,523
Computer Equipment [Member] | Minimum [Member]
Property Plant And Equipment [Line Items]
Estimated Useful Life		3 years
Computer Equipment [Member] | Maximum [Member]
Property Plant And Equipment [Line Items]
Estimated Useful Life		7 years
Scientific Equipment [Member]
Property Plant And Equipment [Line Items]
Property, Plant and Equipment, gross		$ 12,930	14,962
Scientific Equipment [Member] | Minimum [Member]
Property Plant And Equipment [Line Items]
Estimated Useful Life		3 years
Scientific Equipment [Member] | Maximum [Member]
Property Plant And Equipment [Line Items]
Estimated Useful Life		10 years
Furniture [Member]
Property Plant And Equipment [Line Items]
Property, Plant and Equipment, gross		$ 3,128	3,446
Furniture [Member] | Minimum [Member]
Property Plant And Equipment [Line Items]
Estimated Useful Life		3 years
Furniture [Member] | Maximum [Member]
Property Plant And Equipment [Line Items]
Estimated Useful Life		10 years
Manufacturing Equipment [Member]
Property Plant And Equipment [Line Items]
Property, Plant and Equipment, gross		$ 20,583	25,159
Manufacturing Equipment [Member] | Minimum [Member]
Property Plant And Equipment [Line Items]
Estimated Useful Life		7 years
Manufacturing Equipment [Member] | Maximum [Member]
Property Plant And Equipment [Line Items]
Estimated Useful Life		10 years
Leasehold Improvements [Member]
Property Plant And Equipment [Line Items]
Estimated Useful Life	[1]
Property, Plant and Equipment, gross	[1]	$ 23,243	$ 35,595
[1]	The estimated useful life of the leasehold improvements is the lesser of the lease term or the estimated useful life.

Note 6 - Property and Equipme45

Note 6 - Property and Equipment (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Property Plant And Equipment [Abstract]
Depreciation, Depletion and Amortization	$ 7,337,000	$ 6,249,000	$ 5,291,000
Construction in progress	$ 9,663,000	$ 6,857,000

Note 7 - Commitments and Cont46

Note 7 - Commitments and Contingencies - Summary of Future Minimum Commitments for Operating Leases (Details) $ in Thousands	Dec. 31, 2017USD ($)
Years ending December 31,
2,018	$ 3,310
2,019	3,405
2,020	3,495
2,021	2,526
2,022	1,283
Thereafter	13,146
Total	$ 27,165

Note 7 - Commitments and Cont47

Note 7 - Commitments and Contingencies (Details Textual)

Jan. 17, 2018

Oct. 31, 2017USD ($)

Oct. 20, 2017USD ($)

Oct. 01, 2017USD ($)

Jul. 12, 2017USD ($)

Apr. 06, 2017USD ($)

Jul. 14, 2016USD ($)

Mar. 01, 2016

Nov. 01, 2015USD ($)

Oct. 02, 2015USD ($)

Jun. 23, 2015USD ($)

Jun. 08, 2015USD ($)

Oct. 30, 2015

Apr. 30, 2015

Mar. 31, 2017USD ($)

Dec. 31, 2016USD ($)

Sep. 30, 2017USD ($)

Dec. 31, 2017USD ($)Device

Dec. 31, 2016USD ($)

Dec. 31, 2015USD ($)

Jun. 30, 2016USD ($)

Commitments And Contingencies [Line Items]

Deferred rent

$ 3,003,000

$ 3,237,000

$ 3,003,000

Operating Leases, Rent Expense, Net

3,335,000

2,757,000

$ 2,445,000

Purchase Obligation

$ 19,500,000

Extended period of agreement

2,020

Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay

6.00%

Defined Contribution Plan, Employer Matching Contribution, Percent of Match

50.00%

Defined contribution plan, employer matching contribution plan expenses

$ 647,000

730,000

670,000

Income Tax benefit

10,820,000

834,000

32,941,000

Litigation Settlement, Expense

$ 3,900,000

159,684,000

$ 3,900,000

10,616,000

U S Department Of Justice [Member]

Commitments And Contingencies [Line Items]

Estimated Contingent Liability

$ 150,000,000

Litigation settlement payment period

5 years

Loss contingency accrual

$ 0

Income Tax benefit

0

Anti-Kickback Statute Litigation [Member] | Settled Litigation [Member]

Commitments And Contingencies [Line Items]

Payments In Question

$ 83,000

Kickbacks [Member] | Settled Litigation [Member]

Commitments And Contingencies [Line Items]

Payments In Question

$ 188,000

Oregon Department of Justice [Member] | Settled Litigation [Member]

Commitments And Contingencies [Line Items]

Litigation Settlement, Amount

$ 1,100,000

State of Illinois [Member] | Settled Litigation [Member]

Commitments And Contingencies [Line Items]

Litigation Settlement, Amount

4,450,000

State of New Hampshire [Member]

Commitments And Contingencies [Line Items]

Charitable Contribution

$ 500,000

State of New Hampshire [Member] | Settled Litigation [Member]

Commitments And Contingencies [Line Items]

Litigation Settlement, Amount

2,900,000

State of Massachusetts [Member] | Settled Litigation [Member]

Commitments And Contingencies [Line Items]

Litigation Settlement, Amount

$ 500,000

State of Arizona [Member] | Subsequent Event [Member]

Commitments And Contingencies [Line Items]

Response period due after amended complaint serves

10 days

Kottayil vs. Insys Pharma, Inc. [Member] | Settled Litigation [Member]

Commitments And Contingencies [Line Items]

Estimated Contingent Liability

9,567,000

Litigation Settlement, Amount

$ 7,317,450

850,000

Loss Contingency, Damages Awarded, Value

$ 7,317,450

Litigation Settlement, Post-Judgment Interest

4.25%

Litigation Settlement, Expense

$ 93,163

Kottayil vs. Insys Pharma, Inc. [Member] | Settled Litigation [Member] | Settlement Interest [Member]

Commitments And Contingencies [Line Items]

Estimated Contingent Liability

2,249,000

Kottayil vs. Insys Pharma, Inc. [Member] | Threatened Litigation [Member]

Commitments And Contingencies [Line Items]

Loss Contingency, Damages Sought, Value

$ 3,630,000

Horizon Blue Cross Blue Shield of New Jersey [Member]

Commitments And Contingencies [Line Items]

Loss Contingency, Damages Sought, Value

$ 4,000,000

Renaissance [Member]

Commitments And Contingencies [Line Items]

Purchase Obligation Per Calendar Year

$ 4,000,000

Purchase Obligation

$ 16,000,000

$ 49,740,000

Contractual Obligation

12,000,000

Renaissance [Member] | Loss on Long-term Purchase Commitment [Member] | Cost of Revenue [Member]

Commitments And Contingencies [Line Items]

Loss on purchase commitments

1,035,000

Maximum [Member] | U S Department Of Justice [Member]

Commitments And Contingencies [Line Items]

Estimated Contingent Liability

150,000,000

Loss Contingency, Estimate of Possible Loss

$ 75,000,000

Maximum [Member] | Kottayil vs. Insys Pharma, Inc. [Member] | Threatened Litigation [Member]

Commitments And Contingencies [Line Items]

Loss Contingency, Estimate of Possible Loss

3,630,000

Minimum [Member] | Kottayil vs. Insys Pharma, Inc. [Member] | Threatened Litigation [Member]

Commitments And Contingencies [Line Items]

Loss Contingency, Estimate of Possible Loss

$ 0

Minimum [Member] | Anthem Blue Cross of California Vs Insys Therapeutics Inc [Member]

Commitments And Contingencies [Line Items]

Loss Contingency, Damages Sought, Value

$ 19,000,000

Aptargroup, Inc [Member]

Commitments And Contingencies [Line Items]

Join agreement period

7 years

Purchase Obligation

$ 9,000,000

$ 20,790,000

Contractual Obligation

$ 7,500,000

Minimum devices to be purchased to evade annual flat fee | Device

1,000,000

Aptargroup, Inc [Member] | Maximum [Member]

Commitments And Contingencies [Line Items]

Tiered royalties as percentage of net revenue

1.00%

Purchase Obligation Per Calendar Year

$ 500,000

Letter of Credit Per Facility Lease Agreement [Member]

Commitments And Contingencies [Line Items]

Unused letter of credit

$ 400,000

Note 7 - Commitments and Cont48

Note 7 - Commitments and Contingencies - Summary of Aggregate Minimum Purchase Commitments (Details) $ in Thousands	Dec. 31, 2017USD ($)
Years ending December 31,
2,018	$ 5,500
2,019	6,000
2,020	6,000
2,021	2,000
Total	$ 19,500

Note 8 - Equity (Details Textua

Note 8 - Equity (Details Textual)	May 05, 2015$ / shares	Feb. 26, 2014$ / shares	Aug. 31, 2014Vote$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares	Dec. 31, 2016$ / sharesshares	Nov. 05, 2015USD ($)	May 06, 2014$ / sharesshares	May 05, 2014shares
Class Of Stock [Line Items]
Preferred Stock, Par or Stated Value Per Share				$ 0.01	$ 0.01
Common Stock, Par or Stated Value Per Share	$ 0.01			$ 0.01	$ 0.01		$ 0.01
Stockholders' Equity Note, Stock Split, Conversion Ratio	2	1.5
Stock Issued during Period Per Share, Stock Split	1	0.5
Common Stock, Shares Authorized | shares				100,000,000	100,000,000		100,000,000	50,000,000
Stock Repurchase Program, Authorized Amount | $						$ 50,000,000
Pre-split Basis [Member]
Class Of Stock [Line Items]
Common Stock, Par or Stated Value Per Share		$ 0.0002145
Common Stock [Member]
Class Of Stock [Line Items]
Preferred Stock, Par or Stated Value Per Share			$ 0.001
Common Stock, Par or Stated Value Per Share			$ 0.01
Dividend declared, number of Series A Junior Participating Preferred Stock entitled per right | shares			0.01
Preferred Stock Purchase Price			$ 160
Minimum Ownership Percentage Acquired to Trigger Preferred Stock Purchase Rights			15.00%
Rights expiry period			10 years
Preferred Stock, Dividend Rate, Per-Dollar-Amount			$ 1
Multiple used to Determine Preferred Stock Dividend			100
Preferred Stock, Liquidation Preference Per Share			$ 100
Number of Votes for each Preferred Share | Vote			100
Kapoor Notes [Member]
Class Of Stock [Line Items]
Stock Repurchase Program, Remaining Authorized Amount | $				$ 17,442,000

Note 8 - Equity - Summary of Sh

Note 8 - Equity - Summary of Share Repurchase Activity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Equity [Abstract]
Number of Shares Purchased, Beginning Balance	1,403,275	560,200
Number of Shares Purchased during Period	0	843,075
Number of Shares Purchased, Ending Balance	1,403,275	1,403,275
Cost of Share Purchases, Beginning Balance	$ 32,558,000	$ 16,459,000
Cost of Share Purchases during Period	0	16,099,000
Cost of Share Purchases, Ending Balance	$ 32,558,000	$ 32,558,000

Note 9 - Stock-based Compensa51

Note 9 - Stock-based Compensation (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	6,332,415	7,300,873	7,138,089	7,707,162
Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost	$ 1,450,000	$ 3,878,000	$ 4,867,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	21,748,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	14,511,000	19,970,000	25,392,000
Proceeds from Stock Options Exercised	4,545,000	3,803,000	9,524,000
Employee Service Share-based Compensation, Tax Benefit from Compensation Expense	$ 0	$ 122,000	$ 13,593,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 6.32	$ 9.20	$ 19.20
Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 7 months 9 days
Restricted Stock Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 21 days
Employee service share-based compensation, nonvested awards, compensation not yet recognized	$ 2,897,000
Employee Stock Purchase Plan 2013 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate	15.00%
Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date	85.00%
Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date	85.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	530,400
Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized, Annual Automatic Increase, Percent	1.00%
Share-based Compensation Arrangement by Share-based Payment Award, Additional Annual Shares Automatically Authorized, Period Increase, Option Shares	600,000
Stock Issued During Period, Shares, Employee Stock Purchase Plans	1,667,773
Employee Stock Purchase Plan 2013 [Member] | Pre-split Basis [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Additional Annual Shares Automatically Authorized, Period Increase, Option Shares	200,000
Equity Incentive Plan 2013 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized, Annual Automatic Increase, Percent		4.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	6,332,415
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	6,232,807

Note 9 - Stock-based Compensa52

Note 9 - Stock-based Compensation - Amounts Recognized in Condensed Consolidated Statements of Income and Comprehensive Income (Loss) with Respect to Stock-Based Compensation Plans (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total cost of stock-based compensation	$ 16,015	$ 21,589	$ 21,882
Research and Development Expense [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total cost of stock-based compensation	3,217	3,931	2,133
General and Administrative Expense [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total cost of stock-based compensation	$ 12,798	$ 17,658	$ 19,749

Note 9 - Stock-based Compensa53

Note 9 - Stock-based Compensation - Summary of Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Shares, Outstanding, Beginning balance	7,300,873	7,138,089	7,707,162
Number of Shares, Granted	2,577,650	2,337,043	1,733,671
Number of Shares, Cancelled	(2,059,826)	(1,536,538)	(695,061)
Number of Shares, Expired	(9,834)
Number of Shares, Exercised	(1,476,448)	(637,721)	(1,607,683)
Number of Shares, Outstanding, Ending balance	6,332,415	7,300,873	7,138,089
Number of Shares, Vested and exercisable as of December 31, 2016	3,499,957
Weighted Average Exercise Price, Outstanding, Beginning balance	$ 12.36	$ 7.57	$ 2.90
Weighted Average Exercise Price, Granted	10.73	14.86	14.57
Weighted Average Exercise Price, Cancelled	17.76	18.67	7.71
Weighted Average Exercise Price, Expired	20.13
Weighted Average Exercise Price, Exercised	3.08	5.96	2.48
Weighted Average Exercise Price, Outstanding, Ending balance	12.10	$ 12.36	$ 7.57
Weighted Average Exercise Price, Vested and exercisable as of December 31, 2016	$ 11.43
Weighted Average Remaining Contractual Term, Outstanding as of December 31, 2016	7 years 4 months 24 days
Weighted Average Remaining Contractual Term, Vested and exercisable as of December 31, 2016	6 years 1 month 6 days
Aggregate Intrinsic Value, Exercised	$ 10.6
Aggregate Intrinsic Value, Outstanding as of December 31, 2016	12
Aggregate Intrinsic Value, Vested and exercisable as of December 31, 2016	$ 10.2

Note 9 - Stock-based Compensa54

Note 9 - Stock-based Compensation - Summary of Weighted-Average Assumptions used to Estimate Fair Value of Employee Stock Options (Detail)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Expected volatility	57.80%	63.30%	69.90%
Risk-free interest rate	2.20%	1.60%	1.90%
Expected term (in years)	6 years 10 months 25 days	7 years	7 years
Expected dividend yield	0.00%	0.00%	0.00%

Note 9 - Stock-based Compensa55

Note 9 - Stock-based Compensation - Summary of Restricted Stock Unit Activity (Detail) - Restricted Stock Units [Member]	12 Months Ended
	Dec. 31, 2017$ / sharesshares
Number of Shares [Abstract]
Number of Units, Granted | shares	481,250
Number of Units, Cancelled | shares	(85,350)
Number of Units, Exercised | shares	(14,000)
Number of Units, Outstanding, Ending balance | shares	381,900
Weighted Average Grant Date Fair Value Per Unit [Abstract]
Weighted Average Grant-Date Fair Value Per Unit, Outstanding, Beginning balance	$ 0
Weighted Average Grant-Date Fair Value Per Unit, Granted	10.74
Weighted Average Grant-Date Fair Value Per Unit, Cancelled	12.54
Weighted Average Grant-Date Fair Value Per Unit, Exercised	12.65
Weighted Average Grant-Date Fair Value Per Unit, Outstanding, Ending balance	$ 10.27

Note 10 - Income Taxes - Income

Note 10 - Income Taxes - Income Tax Expense (Benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Current income taxes:
Federal	$ (12,474)	$ 5,916	$ 31,383
State and local	51	554	6,473
Total current income tax	(12,423)	6,470	37,856
Deferred income taxes:
Federal	20,178	(7,762)	(3,759)
State and local	3,065	2,126	(1,156)
Total deferred income tax	23,243	(5,636)	(4,915)
Income tax expense	$ 10,820	$ 834	$ 32,941

Note 10 - Income Taxes (Details

Note 10 - Income Taxes (Details Textual) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 22, 2017	Dec. 21, 2017	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Line Items]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent						35.00%	35.00%	35.00%
Orphan drug credit percentage		25.00%	50.00%
Provisional estimate				$ 7,500		$ 7,500
Deferred Tax Assets, Increase in Valuation Allowance						$ 26,800
Effective Income Tax Rate Reconciliation, Percent						(5.00%)	9.90%	36.10%
Unrecognized Tax Benefits	$ 10,134			10,134		$ 10,134	$ 9,800	$ 8,920
Unrecognized Tax Benefits that would Affect Effective Tax Rate if Recognized	10,100			10,100		10,100
Unrecognized Tax Benefits, Interest on Income Taxes Accrued	1,300			1,300		1,300
Tax Credits [Member]
Income Tax Disclosure [Line Items]
Unrecognized Tax Benefits	2,800			2,800		2,800
State and Local Income Tax Filing Positions [Member]
Income Tax Disclosure [Line Items]
Unrecognized Tax Benefits	5,400			5,400		5,400
Other Permanent Differences [Member]
Income Tax Disclosure [Line Items]
Unrecognized Tax Benefits	1,900			1,900		1,900
Domestic Tax Authority [Member]
Income Tax Disclosure [Line Items]
Operating Loss Carryforwards	1,100			1,100		1,100
Tax Credits	11,400
State and Local Jurisdiction [Member]
Income Tax Disclosure [Line Items]
Operating Loss Carryforwards	236,600			$ 236,600		$ 236,600
Tax Credits	$ 5,600
Scenario Forecast [Member]
Income Tax Disclosure [Line Items]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent					21.00%

Note 10 - Income Taxes - Deferr

Note 10 - Income Taxes - Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Deferred income tax assets:
NOLs and credits	$ 38,858	$ 27,046
Start-up expenditures	1,480	2,604
Stock-based compensation	6,439	11,727
Allowances	931	1,264
Expenses currently not deductible for tax purposes	6,838	10,652
Deferred revenue	251
Other	1,167	1,963
Gross deferred tax assets	55,964	55,256
Deferred income tax asset valuation allowance	(50,339)	(23,508)
Deferred income tax assets	5,625	31,748
Deferred income tax liabilities:
Federal impact of state taxes	(643)	(1,073)
Property and equipment	(4,058)	(6,246)
Prepaid expenses	$ (924)	(1,186)
Net deferred income tax assets		$ 23,243

Note 10 - Income Taxes - Effect

Note 10 - Income Taxes - Effective Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	35.00%	35.00%	35.00%
Increase (reduction) of income taxes resulting from:
State income taxes, net of federal benefit	0.70%	(0.10%)	2.30%
Non-deductible litigation expense		3.40%	3.50%
Non-deductible and includible items	(0.90%)	7.50%	0.70%
Non-deductible lobbying expense		8.30%
Research and other credits	1.10%	(63.50%)	(5.40%)
Uncertain tax positions	(0.10%)	4.20%	2.70%
Domestic manufacturing deduction		(14.60%)	(3.00%)
Stock based compensation	(1.30%)	5.10%	0.40%
Tax exempt interest income		(1.50%)
Non-deductible settlement expenses	(24.30%)
Adjustment of net deferred tax assets for U.S. tax reform	(3.50%)
Other		0.60%
Change in valuation allowance	(11.70%)	25.50%	(0.10%)
Total provision for income taxes	(5.00%)	9.90%	36.10%

Note 10 - Income Taxes - Beginn

Note 10 - Income Taxes - Beginning and Ending Amounts of Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Reconciliation Of Unrecognized Tax Benefits Excluding Amounts Pertaining To Examined Tax Returns Roll Forward
Beginning balance	$ 9,800	$ 8,920
Additions based on current year's tax positions	555	758
Deductions based on prior year's tax positions	(239)
Additions based on prior year's tax positions	18	122
Ending balance	$ 10,134	$ 9,800

Note 11 - Net Income (Loss) per

Note 11 - Net Income (Loss) per Share - Computation of Basic and Diluted Net Income (Loss) Per Common Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Historical net income (loss) per share - Basic
Net income (loss)	$ (46,987)	$ (166,320)	$ (8,184)	$ (6,524)	$ (3,652)	$ 2,925	$ 6,027	$ 2,290	$ (228,015)	$ 7,590	$ 58,053
Weighted average number of common shares outstanding									72,259,063	71,618,793	71,592,581
Basic net income (loss) per common share	$ (0.65)	$ (2.30)	$ (0.11)	$ (0.09)	$ (0.05)	$ 0.04	$ 0.08	$ 0.03	$ (3.16)	$ 0.11	$ 0.81
Historical net income (loss) per share - Diluted
Net income (loss)	$ (46,987)	$ (166,320)	$ (8,184)	$ (6,524)	$ (3,652)	$ 2,925	$ 6,027	$ 2,290	$ (228,015)	$ 7,590	$ 58,053
Weighted average number of common shares outstanding									72,259,063	71,618,793	71,592,581
Effect of dilutive stock options										2,527,125	4,115,070
Weighted average number of common shares outstanding									72,259,063	74,145,918	75,707,651
Diluted net income (loss) per common share	$ (0.65)	$ (2.30)	$ (0.11)	$ (0.09)	$ (0.05)	$ 0.04	$ 0.08	$ 0.03	$ (3.16)	$ 0.10	$ 0.77

Note 11 - Net Income (Loss) p62

Note 11 - Net Income (Loss) per Share (Details Textual) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Earnings Per Share [Abstract]
Anti-dilutive securities excluded from computation of earnings per share, Shares	1,677,040	2,596,324	1,460,986

Note 12 - Product Lines, Conc63

Note 12 - Product Lines, Concentration of Credit Risk and Significant Customers (Details Textual)	12 Months Ended
	Dec. 31, 2017USD ($)ProductLineWholesaler	Dec. 31, 2016Wholesaler	Dec. 31, 2015Wholesaler
Product Lines Concentration Of Credit Risk And Significant Customers [Line Items]
Number of Product Lines | ProductLine	2
Cash, FDIC Insured Amount | $	$ 250,000
Customer Concentration Risk [Member] | Sales Revenue Net [Member] | Pharmaceutical Wholesaler Customer One [Member]
Product Lines Concentration Of Credit Risk And Significant Customers [Line Items]
Concentration Risk, Percentage	26.00%	17.00%	32.00%
Customer Concentration Risk [Member] | Sales Revenue Net [Member] | Pharmaceutical Wholesaler Customer Two [Member]
Product Lines Concentration Of Credit Risk And Significant Customers [Line Items]
Concentration Risk, Percentage	18.00%	16.00%	20.00%
Customer Concentration Risk [Member] | Sales Revenue Net [Member] | Pharmaceutical Wholesaler Customer Three [Member]
Product Lines Concentration Of Credit Risk And Significant Customers [Line Items]
Concentration Risk, Percentage	11.00%	15.00%	17.00%
Customer Concentration Risk [Member] | Sales Revenue Net [Member] | Pharmaceutical Wholesaler Customer Four [Member]
Product Lines Concentration Of Credit Risk And Significant Customers [Line Items]
Concentration Risk, Percentage		14.00%	14.00%
Customer Concentration Risk [Member] | Sales Revenue Net [Member] | Pharmaceutical Wholesalers [Member]
Product Lines Concentration Of Credit Risk And Significant Customers [Line Items]
Concentration Risk, Number of Customers	3	4	4
Customer Concentration Risk [Member] | Sales Revenue Net [Member] | Specialty Pharmaceutical Retailers Customer One [Member]
Product Lines Concentration Of Credit Risk And Significant Customers [Line Items]
Concentration Risk, Percentage	23.00%	32.00%
Customer Concentration Risk [Member] | Sales Revenue Net [Member] | Specialty Pharmaceutical Retailers Customer Two [Member]
Product Lines Concentration Of Credit Risk And Significant Customers [Line Items]
Concentration Risk, Percentage	14.00%
Customer Concentration Risk [Member] | Sales Revenue Net [Member] | Specialty Pharmaceutical Retailers [Member]
Product Lines Concentration Of Credit Risk And Significant Customers [Line Items]
Concentration Risk, Number of Customers	2	1
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Pharmaceutical Wholesaler Customer One [Member]
Product Lines Concentration Of Credit Risk And Significant Customers [Line Items]
Concentration Risk, Percentage	44.00%	36.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Pharmaceutical Wholesaler Customer Two [Member]
Product Lines Concentration Of Credit Risk And Significant Customers [Line Items]
Concentration Risk, Percentage	18.00%	23.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Pharmaceutical Wholesaler Customer Three [Member]
Product Lines Concentration Of Credit Risk And Significant Customers [Line Items]
Concentration Risk, Percentage	10.00%	21.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Pharmaceutical Wholesaler Customer Four [Member]
Product Lines Concentration Of Credit Risk And Significant Customers [Line Items]
Concentration Risk, Percentage		13.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Pharmaceutical Wholesalers [Member]
Product Lines Concentration Of Credit Risk And Significant Customers [Line Items]
Concentration Risk, Number of Customers	3	4
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Specialty Pharmaceutical Retailers Customer One [Member]
Product Lines Concentration Of Credit Risk And Significant Customers [Line Items]
Concentration Risk, Percentage	13.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Specialty Pharmaceutical Retailers Customer Two [Member]
Product Lines Concentration Of Credit Risk And Significant Customers [Line Items]
Concentration Risk, Percentage	12.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Specialty Pharmaceutical Retailers [Member]
Product Lines Concentration Of Credit Risk And Significant Customers [Line Items]
Concentration Risk, Number of Customers	2

Note 12 - Product Lines, Conc64

Note 12 - Product Lines, Concentration of Credit Risk and Significant Customers - Summary of Net Revenue by Product Line and Percentages (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Segment Reporting Information [Line Items]
Revenues	$ 31,485	$ 30,670	$ 42,576	$ 35,962	$ 54,860	$ 57,773	$ 69,221	$ 60,421	$ 140,693	$ 242,275	$ 330,323
SUBSYS [Member]
Segment Reporting Information [Line Items]
Revenues									139,250	$ 242,275	329,040
SYNDROS [Member]
Segment Reporting Information [Line Items]
Revenues									$ 1,443
Dronabinol SG Capsule [Member]
Segment Reporting Information [Line Items]
Revenues											$ 1,283

Note 12 - Product Lines, Conc65

Note 12 - Product Lines, Concentration of Credit Risk and Significant Customers - Percentage of Revenue by Route to Market (Details) - Sales Revenue, Product Line [Member] - Customer Concentration Risk [Member]	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Segment Reporting Information [Line Items]
Concentration Risk Percentage	100.00%	100.00%	100.00%
Pharmaceutical Wholesalers [Member]
Segment Reporting Information [Line Items]
Concentration Risk Percentage	63.00%	67.00%	95.00%
Specialty Pharmaceutical Retailers [Member]
Segment Reporting Information [Line Items]
Concentration Risk Percentage	37.00%	33.00%	5.00%

Note 13 - Supplemental Financ66

Note 13 - Supplemental Financial Information - Allowances for Accounts Receivables (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Allowance for Doubtful Accounts [Member]
Valuation And Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Year	$ 685	$ 811	$ 398
Charged to Costs and Expenses		(96)	413
Utilization	(685)	(30)
Balance at End of Year		685	811
Allowance for Sales Wholesaler Discounts Prompt Pay Discounts Stocking Allowances and Chargebacks [Member]
Valuation And Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Year	5,459	7,556	5,418
Charged to Costs and Expenses	14,525	27,968	38,036
Utilization	(16,152)	(30,065)	(35,898)
Balance at End of Year	$ 3,832	$ 5,459	$ 7,556

Note 14 - Quarterly Results o67

Note 14 - Quarterly Results of Operations (Unaudited) - Schedule of Quarterly Results of Operations (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Net revenue	$ 31,485	$ 30,670	$ 42,576	$ 35,962	$ 54,860	$ 57,773	$ 69,221	$ 60,421	$ 140,693	$ 242,275	$ 330,323
Gross profit (1)	26,874	23,198	38,655	31,323	45,055	53,096	62,948	55,783	120,050	216,882	301,469
Net income (loss)	$ (46,987)	$ (166,320)	$ (8,184)	$ (6,524)	$ (3,652)	$ 2,925	$ 6,027	$ 2,290	$ (228,015)	$ 7,590	$ 58,053
Net income (loss) per common share:
Basic	$ (0.65)	$ (2.30)	$ (0.11)	$ (0.09)	$ (0.05)	$ 0.04	$ 0.08	$ 0.03	$ (3.16)	$ 0.11	$ 0.81
Diluted	$ (0.65)	$ (2.30)	$ (0.11)	$ (0.09)	$ (0.05)	$ 0.04	$ 0.08	$ 0.03	$ (3.16)	$ 0.10	$ 0.77

Note 14 - Quarterly Results o68

Note 14 - Quarterly Results of Operations (Unaudited) - Schedule of Quarterly Results of Operations (Parenthetical) (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Sep. 30, 2017
Quarterly Financial Information [Line Items]
Inventory obsolescence reserve			$ 6,186	$ 7,397	$ (336)
Provisional tax expense related to the 2017 Tax Act	$ 7,500		7,500
Valuation allowance of deferred tax assets, accrual	22,600		22,600
Charges related to litigation award and settlements		$ 3,900	$ 159,684	$ 3,900	$ 10,616
Inventory Valuation and Obsolescence [Member]
Quarterly Financial Information [Line Items]
Inventory obsolescence reserve	$ 2,100
SUBSYS [Member] | Inventory Valuation and Obsolescence [Member]
Quarterly Financial Information [Line Items]
Inventory obsolescence reserve		$ 5,800
U S Department Of Justice [Member]
Quarterly Financial Information [Line Items]
Estimated Contingent Liability						$ 150,000